ticlopidine has been researched along with Coronary Restenosis in 272 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
Excerpt | Relevance | Reference |
---|---|---|
" Direct comparison of the antiplatelet effects between ticagrelor and high-dose clopidogrel has not yet been reported in acute myocardial infarction (AMI) or coronary artery in-stent restenosis (ISR) patients with HTPR." | 9.20 | Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. ( Cao, A; Chen, T; Li, P; Liu, J; Liu, Y; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X, 2015) |
"ST-segment elevation myocardial infarction patients undergoing primary PCI in a regional STEMI network who received earlier pretreatment with a 600-mg loading dose of clopidogrel had less ischemic complications without increased bleeding or mortality." | 9.14 | Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention. ( Burke, MN; Duval, S; Henry, TD; Larson, DM; Lips, DL; Sharkey, SS; Solie, C; Steinhubl, S; Tschautscher, C, 2010) |
"The PRODIGY trial aims to assess whether 24 months of clopidogrel therapy improves cardiovascular outcomes after coronary intervention in a broad all-comer patient population receiving a balanced mixture of stents with various anti-intimal hyperplasia potency." | 9.14 | Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment ( Arcozzi, C; Borghesi, M; Campo, G; Cangiano, E; Cavazza, C; Colombo, F; Ferrari, F; Ferrari, R; Frangione, A; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Zuffi, A, 2010) |
"Although cilostazol has reduced the extent of neointimal hyperplasia and restenosis in patients after bare-metal stent implantation, it is not known whether this effect occurs after DES implantation in diabetic patients." | 9.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
"Sirolimus-eluting stents (SESs) recently proved to be superior to bare metal stents (BMSs) in decreasing the need for repeat revascularization in patients with ST-segment elevation myocardial infarction (STEMI) at 1 year." | 9.12 | Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). ( Daemen, J; de Jaegere, PP; García-García, HM; Kukreja, N; Serruys, PW; Sianos, G; Tanimoto, S; van de Sande, M; van Domburg, RT, 2007) |
"Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents." | 9.10 | A paclitaxel-eluting stent for the prevention of coronary restenosis. ( Choi, D; Ho, DS; Hong, MK; Jang, Y; Lam, R; Lee, CW; Mintz, GS; Park, SJ; Park, SW; Raizner, AE; Shim, WH; Weissman, NJ, 2003) |
" These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)." | 8.90 | Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014) |
"Compared to clopidogrel and prasugrel, ticagrelor reduced neointimal formation, endothelial dysfunction, and peri-strut inflammation." | 7.85 | Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model. ( Chang, KS; Hong, YJ; Jeong, MH; Kim, HK; Kim, JH; Kim, MC; Kim, SS; Lim, HC; Lim, KS; Park, KH, 2017) |
"The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 7.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)." | 7.73 | Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006) |
"This study investigated the safety and efficacy of sirolimus-eluting stents (SESs) on early and late outcomes in patients with acute myocardial infarction." | 7.73 | [Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction]. ( Asai, T; Gochi, T; Hiramitsu, S; Hishida, H; Katoh, T; Maekawa, H; Matsushita, T; Morimoto, S; Murakami, Y; Murohara, T; Nomura, M; Okada, T; Ozaki, Y; Shimizu, T; Tani, T; Umeda, H; Watanabe, K; Yokoya, M; Yoshida, N, 2006) |
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 7.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months." | 6.74 | Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009) |
"Rates of bleeding and thrombotic events were not significantly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin responders." | 5.20 | 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. ( Armengaud, J; Barragan, P; Benamer, H; Berland, J; Blanchard, D; Boschat, J; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Druelles, P; Dupouy, P; Endresen, K; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2015) |
"Clopidogrel is indicated for the treatment and prevention of peripheral vascular, cerebrovascular, and coronary artery diseases." | 5.20 | Assessment of the efficacy and tolerability of clopidogrel napadisilate in Korean patients with coronary stenting: a multicenter, prospective, open-label, randomized trial. ( Cho, DK; Kim, SH; Lee, HJ; Lee, HS; Lim, SW; Shin, J; Sung, JH, 2015) |
" Direct comparison of the antiplatelet effects between ticagrelor and high-dose clopidogrel has not yet been reported in acute myocardial infarction (AMI) or coronary artery in-stent restenosis (ISR) patients with HTPR." | 5.20 | Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. ( Cao, A; Chen, T; Li, P; Liu, J; Liu, Y; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X, 2015) |
"The purpose of this pre-specified analysis of the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) was to assess device-specific outcomes relative to different duration of dual antiplatelet therapy (DAPT) after Everolimus- (EES), Paclitaxel (PES), Zotarolimus- (ZES-S) eluting, or bare metal stents (BMS)." | 5.17 | Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). ( Borghesi, M; Ferrari, R; Parrinello, G; Tebaldi, M; Valgimigli, M; Vranckx, P, 2013) |
"A regimen of 24 months of clopidogrel therapy in patients who had received a balanced mixture of drug-eluting or bare-metal stents was not significantly more effective than a 6-month clopidogrel regimen in reducing the composite of death due to any cause, myocardial infarction, or cerebrovascular accident." | 5.16 | Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. ( Borghesi, M; Campo, G; Cangiano, E; Castriota, F; Cavazza, C; Colombo, F; Ferrari, R; Frangione, A; Fucà, G; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2012) |
"The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial included 3602 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention who were randomized to heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) (n=1802) versus bivalirudin monotherapy (n=1800)." | 5.15 | Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. ( Brodie, BR; Caixeta, A; Cristea, E; Dangas, GD; Dudek, D; Guagliumi, G; Lansky, AJ; Mehran, R; Möeckel, M; Parise, H; Peruga, JZ; Stone, GW; Witzenbichler, B, 2011) |
"This multicenter registry documents satisfactory safety and efficacy profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent when used with 6 months of dual antiplatelet therapy in a "real-world" setting." | 5.14 | Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. ( Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H, 2009) |
"ST-segment elevation myocardial infarction patients undergoing primary PCI in a regional STEMI network who received earlier pretreatment with a 600-mg loading dose of clopidogrel had less ischemic complications without increased bleeding or mortality." | 5.14 | Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention. ( Burke, MN; Duval, S; Henry, TD; Larson, DM; Lips, DL; Sharkey, SS; Solie, C; Steinhubl, S; Tschautscher, C, 2010) |
"The PRODIGY trial aims to assess whether 24 months of clopidogrel therapy improves cardiovascular outcomes after coronary intervention in a broad all-comer patient population receiving a balanced mixture of stents with various anti-intimal hyperplasia potency." | 5.14 | Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment ( Arcozzi, C; Borghesi, M; Campo, G; Cangiano, E; Cavazza, C; Colombo, F; Ferrari, F; Ferrari, R; Frangione, A; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Zuffi, A, 2010) |
"The ISAR-REACT 2 trial was designed to assess the effect of abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after a 600-mg loading dose of clopidogrel." | 5.13 | Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes. ( Dirschinger, J; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Pache, J; Schömig, A; Seyfarth, M, 2008) |
"Although cilostazol has reduced the extent of neointimal hyperplasia and restenosis in patients after bare-metal stent implantation, it is not known whether this effect occurs after DES implantation in diabetic patients." | 5.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
"Sirolimus-eluting stents (SESs) recently proved to be superior to bare metal stents (BMSs) in decreasing the need for repeat revascularization in patients with ST-segment elevation myocardial infarction (STEMI) at 1 year." | 5.12 | Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). ( Daemen, J; de Jaegere, PP; García-García, HM; Kukreja, N; Serruys, PW; Sianos, G; Tanimoto, S; van de Sande, M; van Domburg, RT, 2007) |
"The findings of this study do not support a significant impact of abciximab on the risk of death and myocardial infarction in diabetic patients undergoing percutaneous coronary interventions after pretreatment with a 600-mg loading dose of clopidogrel at least 2 hours before the procedure." | 5.11 | Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. ( Berger, PP; Bollwein, H; Dibra, A; Dirschinger, J; Dotzer, F; Kastrati, A; Mehilli, J; Pache, J; Schömig, A; Schühlen, H; von Beckerath, N, 2004) |
"Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents." | 5.10 | A paclitaxel-eluting stent for the prevention of coronary restenosis. ( Choi, D; Ho, DS; Hong, MK; Jang, Y; Lam, R; Lee, CW; Mintz, GS; Park, SJ; Park, SW; Raizner, AE; Shim, WH; Weissman, NJ, 2003) |
" These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)." | 4.90 | Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014) |
" In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis." | 4.88 | Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012) |
"Clopidogrel is recommended with aspirin for patients who undergo coronary artery bypass grafting (CABG) after non-ST elevation myocardial infarctions." | 4.85 | Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients. ( Mathew, ST; Owora, A; Patel, JH; Stoner, JA; Thadani, U, 2009) |
"The present review focuses on the roles of thromboxane A2 (TxA2) in arterial thrombosis, atherogenesis, vascular stent-related ischemic events and renal proteinuria." | 4.85 | Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. ( Alberts, P; Bounameaux, H; Fontana, P; Mann, J; Sakariassen, KS; Sorensen, AS, 2009) |
" In addition to aspirin, whose benefit has been clearly demonstrated in all forms of ischemic heart disease, clopidogrel, given before and after cardiac catheterization, also reduces the rate of thrombosis after stent placement." | 4.82 | [Advances in adjunctive pharmacological therapy for percutaneous coronary interventions]. ( Benito, B; Betriu, A; Masotti, M, 2005) |
" In elective de novo lesions has shown remarkably clear lumens at follow-up angiography and intravascular ultrasound within the stented segments were observed with no lesion progression at the stent margins or thrombosis after a 2 month regimen of aspirin, and ticlopodine or clopidogrel." | 4.81 | Sirolimus-eluting stents: a review of experimental and clinical findings. ( Albiero, R; Colombo, A; Corvaja, N; Di Mario, C; Falotico, R; Stankovic, G; Takagi, T; Toutouzas, K, 2002) |
"Compared to clopidogrel and prasugrel, ticagrelor reduced neointimal formation, endothelial dysfunction, and peri-strut inflammation." | 3.85 | Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model. ( Chang, KS; Hong, YJ; Jeong, MH; Kim, HK; Kim, JH; Kim, MC; Kim, SS; Lim, HC; Lim, KS; Park, KH, 2017) |
" While, the incidence of adverse side effects tended to be lower, they were not statistically significant in patients with aspirin plus cilostazol." | 3.81 | Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. ( Hashiguchi, M; Kishino, S; Mochizuki, M; Nakazawa, R; Ohno, K; Shiga, T, 2004) |
"The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 3.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
"The authors studied efficacy of the generic clopidogrel Еgithromb manufactured by EGIS PHARMACEUTICALS (Hungary) based on clinical data and parameters of light aggregometry in a total of 30 patients subjected to planned subcutaneous coronary intervention for stable angina pectoris." | 3.79 | [Assessment of clinical and antiaggregation efficacy of generic clopidogrel 'Egithromb' in roentgenosurgical practice]. ( Faĭl', IL; Loenko, VB; Smialovskiĭ, DV; Sorokina, EA, 2013) |
" Long-term administration of cilostazol is more effective in reducing neointimal formation at non-overlapping segments of BESs in a porcine coronary model." | 3.79 | The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model. ( Ahn, Y; Cho, JG; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, JM; Kim, KH; Lee, KH; Lim, KS; Park, DS; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS, 2013) |
"Between September 2007 and April 2010, twelve patients receiving double antithrombotic therapy (clopidogrel+acetylsalicylic acid) underwent transurethral resection of bladder cancer." | 3.77 | Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy. ( Arena, D; Bozzini, G; Carmignani, L; Casellato, S; Lunelli, L; Picozzi, S; Stubinski, R, 2011) |
"Reducing the dose of sirolimus eluting from a biocompatible HAp coated stent reduces signs of delayed vascular healing, without affecting neointimal hyperplasia." | 3.75 | Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing. ( Peters-Krabbendam, I; Serruys, PW; Sorop, O; van Beusekom, HM; van der Giessen, WJ, 2009) |
"This study investigated the safety and efficacy of sirolimus-eluting stents (SESs) on early and late outcomes in patients with acute myocardial infarction." | 3.73 | [Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction]. ( Asai, T; Gochi, T; Hiramitsu, S; Hishida, H; Katoh, T; Maekawa, H; Matsushita, T; Morimoto, S; Murakami, Y; Murohara, T; Nomura, M; Okada, T; Ozaki, Y; Shimizu, T; Tani, T; Umeda, H; Watanabe, K; Yokoya, M; Yoshida, N, 2006) |
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)." | 3.73 | Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006) |
"Although drug-eluting stents (DES) significantly reduce restenosis, they require 3 to 6 months of thienopyridine therapy to prevent stent thrombosis." | 3.73 | Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. ( Bach, RG; Cohen, DJ; Decker, C; Jones, PG; Kettelkamp, R; Khanal, S; Krumholz, HM; Messenger, JC; Peterson, ED; Rumsfeld, JS; Spertus, JA; Vance, C, 2006) |
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 3.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
"Our study offers preliminary evidence that patients receiving a new PCI procedure for ISR may benefit from long-term administration of aspirin plus clopidogrel." | 2.79 | Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). ( Biscaglia, S; Campo, G; Ferrari, R; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2014) |
"Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for ≥ 3 months or up to 12 months after implantation." | 2.79 | Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. ( Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W, 2014) |
"tirofiban may allow temporary withdrawal of oral clopidogrel without increasing the risk of bleeding." | 2.75 | Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. ( Barlocco, F; Caracciolo, M; D'Urbano, M; De Servi, S; Klugmann, S; Mariani, G; Nichelatti, M; Savonitto, S, 2010) |
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months." | 2.74 | Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009) |
"0001), and major adverse cardiac events (8." | 2.73 | Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). ( Holmes, DR; Kuntz, RE; Leon, MB; Mishkel, G; Moses, JW; Popma, JJ; Raizner, AE; Satler, LF; Teirstein, PS; Wang, P; Weisz, G; Wilensky, RL, 2007) |
"Sarpogrelate treatment reduces restenosis after coronary stenting, which suggests that serotonin released from activated platelets may play an important role in stent restenosis." | 2.71 | Sarpogrelate treatment reduces restenosis after coronary stenting. ( Fujita, M; Ho, M; Ishii, K; Miki, O; Miwa, K; Miyamoto, A; Mizuno, K; Tsukahara, R, 2003) |
"Trapidil has been shown to prevent restenosis after PTCA." | 2.71 | Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting. ( Balducelli, M; Barlera, S; Bernardi, G; Latini, R; Maggioni, AP; Maresta, A; Moccetti, T; Monici Preti, A; Ribeiro da Silva, EE; Sosa, C; Varani, E, 2005) |
"Cilostazol is a newly developed antiplatelet drug that has been widely applied for clinical use." | 2.70 | Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. ( Inoue, T; Kamishirado, H; Mizoguchi, K; Morooka, S; Nakata, T; Sakuma, M; Takayanagi, K; Uchida, T, 2002) |
"After balloon angioplasty of a subtotal or total coronary occlusion, no reduction in adverse events was observed among patients in whom ticlopidine was added to aspirin, even after adjustment for clinical and lesion characteristics." | 2.70 | Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). ( Berger, PB; Buller, CE; Catellier, D; Dzavik, V; Penn, IM, 2001) |
"In this meta-analysis, TAT was associated with significantly effective outcomes for TLR and TVR without any increase in major adverse events but was associated with tolerance issues compared with DAT after DES implantation." | 2.49 | Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. ( Bonneau, HN; Kaneda, H; Koo, BK; Nagai, R; Sakurai, R, 2013) |
" There is also no significant difference in major adverse cardiac and cerebrovascular events between the 2 therapies, except the smaller occurrence rate of target-lesion revascularization in the triple-therapy group (OR: 0." | 2.48 | The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis. ( He, J; He, Y; Liu, G; Ma, C; Tang, P; Wang, P; Yang, J; Zhou, R; Zhou, S, 2012) |
" If both Clopidogrel and PPI need to be prescribed, a split dosage regimen of PPI in the morning and clopidogrel in the evening can be recommended." | 2.46 | [Dilemma between gastroprotection and cardiovascular prevention]. ( Kandulski, A; Malfertheiner, P; Venerito, M, 2010) |
" The main outcomes of the study included major adverse cardiac events (MACEs) and bleeding events during 12 months of follow-up." | 1.48 | The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. ( Cheng, JH; Feng, ZW; Hu, ZH; Li, XY; Lv, QZ; Shi, HT; Wang, QB; Wang, Z; Wu, HY; Xie, XQ; Xu, Q; Xue, Y, 2018) |
"Coronary pseudoaneurysm after bare-metal stent implantation is a rare event." | 1.39 | A coronary pseudoaneurysm within a restenotic stent treated by implantation of a pericardium-covered stent and drug-eluting balloon. ( Palmieri, C; Vaghetti, M, 2013) |
" The effect of aspirin dosing was evaluated using χ(2) , Cochran-Mantel-Haenszel, and homogeneity testing." | 1.37 | Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents. ( Columbo, J; Cui, J; Davis, M; Giugliano, GR; Lotfi, A; Mulvey, S; Schweiger, M; Wartak, S, 2011) |
"002) and major adverse cardiac events (OR: 0." | 1.36 | Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. ( Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010) |
"Only amlodipine was associated with clopidogrel poor-response." | 1.36 | The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. ( Breet, NJ; de Boer, A; Deneer, VH; Hackeng, CM; Harmsze, AM; Klungel, OH; Robijns, K; Ruven, HJ; Ten Berg, JM; van Werkum, JW, 2010) |
"Serious allergic reactions have also been reported; (6) In most cases, especially when the risk of restenosis is low or moderate, it is better to use a bare metal stent." | 1.35 | Drug-eluting coronary stents: many meta-analyses, little benefit. ( , 2009) |
" We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up." | 1.34 | Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007) |
"Aspirin was given starting 3 days before the intervention and administered for an additional 4 weeks." | 1.33 | Prevention of carotid artery restenosis after sirolimus-coated stent implantation in pigs. ( Claussen, CD; Dinkelborg, LM; Duda, SH; Laule, M; Muschick, P; Reddig, F; Tepe, G; Tielemans, H; Wehrmann, M, 2006) |
" An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations." | 1.33 | Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. ( Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006) |
"Ticlopidine (200 mg/day) was prescribed for at least 12 weeks after SES implantation and for 2 weeks after BMS in addition to aspirin (81-100 mg/day)." | 1.33 | Effectiveness of a sirolimus-eluting stent (Cypher) for diffuse in-stent restenosis inside a bare metal stent. ( Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Ohta, M; Okada, H; Sakamoto, H; Tsurusaki, T, 2006) |
" An adequate dosage of ticlopidine (250 mg twice daily) and aspirin (100 mg/day) led to a lower rate of stent thrombosis (6 of 2,189 cases) than inadequate dosages or missing therapy (12 of 343 cases)." | 1.32 | Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis. ( Hambrecht, R; Hentschel, B; Hüttl, T; Lauer, B; Niebauer, J; Schuler, G; Sick, P; Thiele, H, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 173 (63.60) | 29.6817 |
2010's | 98 (36.03) | 24.3611 |
2020's | 1 (0.37) | 2.80 |
Authors | Studies |
---|---|
Osama, S | 1 |
Wirth, F | 1 |
Zahra, G | 1 |
Barbara, C | 1 |
Xuereb, RG | 1 |
Camilleri, L | 1 |
Azzopardi, LM | 1 |
Capodanno, D | 2 |
Kim, HK | 2 |
Jeong, MH | 5 |
Lim, KS | 2 |
Kim, JH | 6 |
Lim, HC | 1 |
Kim, MC | 1 |
Hong, YJ | 3 |
Kim, SS | 1 |
Park, KH | 3 |
Chang, KS | 1 |
Piccolo, R | 2 |
Feres, F | 5 |
Abizaid, A | 7 |
Gilard, M | 3 |
Morice, MC | 3 |
Hong, MK | 9 |
Kim, HS | 6 |
Colombo, A | 8 |
Bhatt, DL | 5 |
Palmerini, T | 1 |
Stone, GW | 3 |
Windecker, S | 3 |
Valgimigli, M | 8 |
Xue, Y | 1 |
Feng, ZW | 1 |
Li, XY | 1 |
Hu, ZH | 1 |
Xu, Q | 1 |
Wang, Z | 2 |
Cheng, JH | 1 |
Shi, HT | 1 |
Wang, QB | 1 |
Wu, HY | 1 |
Xie, XQ | 1 |
Lv, QZ | 1 |
Núñez-Gil, IJ | 1 |
Aldazábal, A | 1 |
Cerrato, E | 1 |
Salinas, P | 1 |
Pérez-Vizcayno, MJ | 3 |
Fernández-Ortiz, A | 1 |
Zhao, X | 2 |
Wu, H | 1 |
Xu, H | 1 |
Shen, L | 1 |
Fan, B | 1 |
Ge, J | 1 |
Kan, J | 1 |
Chen, F | 1 |
Liu, LY | 1 |
Xu, HM | 1 |
Lin, L | 1 |
Liu, Y | 3 |
Zhao, YY | 1 |
Cheng, JP | 1 |
Chen, SL | 1 |
Loenko, VB | 1 |
Sorokina, EA | 1 |
Faĭl', IL | 1 |
Smialovskiĭ, DV | 1 |
Vaghetti, M | 1 |
Palmieri, C | 1 |
Phankingthongkum, R | 1 |
Panchavinnin, P | 1 |
Chinthammitr, Y | 1 |
Tresukosol, D | 1 |
Chotinaiwattarakul, C | 1 |
Tungsubutra, W | 1 |
Wongpraparut, N | 1 |
Kitrattana, B | 1 |
Leewanun, P | 1 |
Lee, SW | 10 |
Lee, JY | 3 |
Ahn, JM | 1 |
Park, DW | 6 |
Han, S | 1 |
Park, YK | 1 |
Lee, WS | 1 |
Jang, JY | 1 |
Kwon, CH | 1 |
Park, GM | 1 |
Cho, YR | 1 |
Kim, WJ | 3 |
Kang, SJ | 3 |
Kim, YH | 8 |
Lee, CW | 9 |
Kim, JJ | 5 |
Park, SW | 9 |
Park, SJ | 9 |
Musumeci, G | 1 |
Limbruno, U | 2 |
Campo, G | 5 |
Tebaldi, M | 6 |
Vranckx, P | 5 |
Biscaglia, S | 1 |
Tumscitz, C | 4 |
Ferrari, R | 4 |
Borghesi, M | 4 |
Cangiano, E | 3 |
Minarelli, M | 3 |
Scalone, A | 3 |
Cavazza, C | 3 |
Marchesini, J | 3 |
Parrinello, G | 4 |
Youn, YJ | 1 |
Lee, JW | 1 |
Ahn, SG | 1 |
Lee, SH | 2 |
Choi, H | 1 |
Yu, CW | 1 |
Kwon, HM | 2 |
Jang, Y | 3 |
Yoon, J | 2 |
Tang, XF | 1 |
Fan, JY | 1 |
Meng, J | 1 |
Jin, C | 1 |
Yuan, JQ | 1 |
Yang, YJ | 1 |
Camenzind, E | 1 |
Boersma, E | 1 |
Wijns, W | 5 |
Mauri, L | 2 |
Rademaker-Havinga, T | 1 |
Ordoubadi, FF | 1 |
Suttorp, MJ | 1 |
Al Kurdi, M | 1 |
Steg, PG | 2 |
López Mínguez, JR | 1 |
Nogales Asensio, JM | 1 |
Doncel Vecino, LJ | 1 |
Sandoval, J | 1 |
Romany, S | 1 |
Martínez Romero, P | 1 |
Fernández Díaz, JA | 1 |
Fernández Portales, J | 1 |
González Fernández, R | 1 |
Martínez Cáceres, G | 1 |
Merchán Herrera, A | 1 |
Alfonso Manterola, F | 1 |
Une, D | 1 |
Al-Atassi, T | 1 |
Kulik, A | 1 |
Voisine, P | 1 |
Le May, M | 1 |
Ruel, M | 1 |
Barragan, P | 2 |
Noryani, AAL | 1 |
Noor, HA | 1 |
Majwal, T | 1 |
Hovasse, T | 1 |
Castellant, P | 1 |
Schneeberger, M | 1 |
Maillard, L | 1 |
Bressolette, E | 1 |
Wojcik, J | 1 |
Delarche, N | 1 |
Blanchard, D | 2 |
Jouve, B | 1 |
Ormezzano, O | 1 |
Paganelli, F | 2 |
Levy, G | 1 |
Sainsous, J | 1 |
Carrie, D | 2 |
Furber, A | 1 |
Berland, J | 2 |
Darremont, O | 1 |
Le Breton, H | 1 |
Lyuycx-Bore, A | 1 |
Gommeaux, A | 1 |
Cassat, C | 1 |
Kermarrec, A | 1 |
Cazaux, P | 1 |
Druelles, P | 1 |
Dauphin, R | 1 |
Armengaud, J | 1 |
Dupouy, P | 2 |
Champagnac, D | 1 |
Ohlmann, P | 1 |
Endresen, K | 1 |
Benamer, H | 2 |
Kiss, RG | 1 |
Ungi, I | 2 |
Boschat, J | 1 |
Kim, SH | 2 |
Sung, JH | 1 |
Shin, J | 1 |
Lee, HJ | 1 |
Lee, HS | 1 |
Cho, DK | 1 |
Lim, SW | 1 |
Yeh, RW | 1 |
Kereiakes, DJ | 2 |
Patialiakas, A | 1 |
Thury, A | 1 |
McFadden, E | 1 |
Colangelo, S | 1 |
Tondi, S | 1 |
Roffi, M | 2 |
Menozzi, A | 1 |
de Cesare, N | 1 |
Garbo, R | 1 |
Meliga, E | 1 |
Testa, L | 1 |
Gabriel, HM | 1 |
Airoldi, F | 3 |
Ferlini, M | 1 |
Liistro, F | 2 |
Dellavalle, A | 1 |
Briguori, C | 1 |
Kandzari, DE | 1 |
Hernandez-Perez, FJ | 1 |
Garcia-Touchard, A | 1 |
Restrepo-Cordoba, MA | 1 |
Rodriguez-Gonzalez, E | 1 |
Escudier-Villa, JM | 1 |
Cobo-Marcos, M | 1 |
Alonso-Pulpon, L | 1 |
Goicolea-Ruigomez, J | 1 |
Lee, SA | 1 |
Suh, JW | 1 |
Park, JJ | 1 |
Yoon, CH | 1 |
Cho, YS | 1 |
Youn, TJ | 1 |
Chae, IH | 3 |
Choi, DJ | 1 |
Liu, C | 1 |
Liu, M | 2 |
Chen, D | 1 |
Liu, H | 3 |
Jiang, Q | 1 |
Lu, J | 1 |
Zuo, L | 1 |
Azzalini, L | 1 |
Al-Hawwas, M | 1 |
L'Allier, PL | 1 |
Nozari, Y | 1 |
Vosooghi, S | 1 |
Boroumand, M | 1 |
Poorhosseini, H | 1 |
Nematipour, E | 1 |
Salarifar, M | 1 |
Kassaian, SE | 1 |
Amirzadegan, A | 1 |
Alidoosti, M | 1 |
Haji-Zeinali, AM | 1 |
Saroukhani, S | 1 |
Wei, YQ | 1 |
Wang, DG | 1 |
Yang, H | 1 |
Cao, H | 1 |
Capranzano, P | 2 |
Castiglioni, B | 1 |
Li, P | 1 |
Yang, Y | 2 |
Chen, T | 2 |
Cao, A | 1 |
Liu, J | 1 |
Qin, Y | 1 |
Ma, L | 1 |
Kagawa, Y | 1 |
Shiode, N | 1 |
Kawase, T | 1 |
Tamekiyo, H | 1 |
Okimoto, T | 1 |
Hayashi, Y | 2 |
Shah, RR | 1 |
Pillai, A | 1 |
Omar, A | 1 |
Zhao, J | 1 |
Arora, V | 1 |
Kapoor, D | 1 |
Poommipanit, P | 1 |
Sharma, GK | 1 |
Megaly, M | 1 |
Ma, W | 1 |
Liang, Y | 1 |
Zhu, J | 1 |
Feng, G | 1 |
Liu, X | 2 |
Wang, X | 1 |
Gargiulo, G | 1 |
Ariotti, S | 1 |
Santucci, A | 1 |
Baldo, A | 1 |
Franzone, A | 1 |
Magnani, G | 1 |
Marino, M | 1 |
Esposito, G | 1 |
Cho, MH | 1 |
Shin, DW | 1 |
Yun, JM | 1 |
Shin, JH | 1 |
Lee, SP | 1 |
Lee, H | 1 |
Lim, YK | 1 |
Kim, EH | 1 |
Zuliani Mauro, MF | 1 |
Mangione, JA | 1 |
Costa, JR | 4 |
Costa, R | 4 |
Piva E Mattos, LA | 1 |
Staico, R | 4 |
Siqueira, D | 3 |
Sousa, A | 2 |
Goodman, SG | 1 |
Nicolau, JC | 1 |
Requena, G | 1 |
Maguire, A | 1 |
Blankenberg, S | 1 |
Chen, JY | 1 |
Granger, CB | 1 |
Grieve, R | 1 |
Pocock, SJ | 1 |
Simon, T | 1 |
Yasuda, S | 1 |
Vega, AM | 1 |
Brieger, D | 1 |
Shaukat, A | 1 |
Al-Bustami, M | 1 |
Ong, PJ | 1 |
Dixon, SR | 2 |
Grines, CL | 3 |
O'Neill, WW | 2 |
Newsome, LT | 1 |
Weller, RS | 1 |
Gerancher, JC | 1 |
Kutcher, MA | 1 |
Royster, RL | 1 |
Süselbeck, T | 1 |
Haghi, D | 1 |
Borggrefe, M | 1 |
Kaden, JJ | 1 |
Asano, T | 1 |
Kobayashi, Y | 1 |
Fukushima, K | 1 |
Iwata, Y | 1 |
Kitahara, H | 1 |
Ishio, N | 1 |
Kuroda, N | 1 |
Komuro, I | 1 |
Ramsdale, DR | 1 |
Rao, A | 1 |
Asghar, O | 1 |
Ramsdale, KA | 1 |
McKay, E | 1 |
Cervinka, P | 1 |
Bystron, M | 1 |
Spacek, R | 1 |
Kvasnak, M | 1 |
Adhikari, S | 1 |
Jakabcin, J | 1 |
Alfonso, F | 3 |
Hernández, R | 2 |
Bethencourt, A | 1 |
Martí, V | 1 |
López-Mínguez, JR | 1 |
Angel, J | 1 |
Iñiguez, A | 2 |
Morís, C | 1 |
Cequier, A | 1 |
Sabaté, M | 2 |
Escaned, J | 3 |
Jiménez-Quevedo, P | 3 |
Bañuelos, C | 3 |
Suárez, A | 2 |
Macaya, C | 4 |
Siller-Matula, JM | 1 |
Lang, I | 1 |
Christ, G | 3 |
Jilma, B | 1 |
Kleiman, NS | 1 |
Graw, J | 1 |
Schwenk, W | 1 |
Volk, T | 1 |
Amasyali, B | 1 |
Celik, T | 1 |
Iyisoy, A | 2 |
Kilic, A | 1 |
Isik, E | 2 |
Pels, K | 1 |
Schwimmbeck, PL | 1 |
Rosenthal, P | 2 |
Loddenkemper, C | 1 |
Dang-Heine, C | 1 |
Rauch, U | 2 |
Martens, H | 1 |
Schultheiss, HP | 2 |
Dechend, R | 1 |
Deiner, C | 1 |
Brilakis, ES | 1 |
Lichtenwalter, C | 1 |
de Lemos, JA | 1 |
Roesle, M | 1 |
Obel, O | 1 |
Haagen, D | 1 |
Saeed, B | 1 |
Gadiparthi, C | 1 |
Bissett, JK | 1 |
Sachdeva, R | 1 |
Voudris, VV | 1 |
Karyofillis, P | 1 |
Kar, B | 1 |
Rossen, J | 1 |
Fasseas, P | 1 |
Berger, P | 2 |
Banerjee, S | 1 |
Byrne, RA | 3 |
Schulz, S | 3 |
Mehilli, J | 9 |
Iijima, R | 3 |
Massberg, S | 3 |
Neumann, FJ | 2 |
ten Berg, JM | 5 |
Schömig, A | 9 |
Kastrati, A | 9 |
Mirabella, F | 1 |
Francaviglia, B | 1 |
Di Salvo, ME | 1 |
Galassi, AR | 1 |
Ussia, GP | 1 |
Tamburino, C | 3 |
Ben-Dor, I | 1 |
Waksman, R | 7 |
Wozakowska-Kapłon, B | 1 |
Młodnicki, M | 1 |
Gutkowski, W | 1 |
Rogacka, R | 1 |
Chieffo, A | 2 |
Michev, I | 2 |
Latib, A | 1 |
Cosgrave, J | 2 |
Montorfano, M | 1 |
Carlino, M | 1 |
Sangiorgi, GM | 2 |
Castelli, A | 1 |
Godino, C | 1 |
Magni, V | 1 |
Aranzulla, TC | 1 |
Romagnoli, E | 1 |
Bruskina, O | 1 |
Pache, J | 3 |
Seyfarth, M | 2 |
Laugwitz, KL | 1 |
Dirschinger, J | 6 |
Jähne, J | 2 |
Schirren, J | 2 |
Rottbauer, W | 1 |
Katus, HA | 1 |
Bölükbas, S | 1 |
Martens, A | 1 |
Haverich, A | 1 |
Tanajura, LF | 2 |
Mattos, LA | 1 |
Sousa, AG | 2 |
Bonan, R | 2 |
Sousa, JE | 4 |
van der Giessen, WJ | 2 |
Sorop, O | 1 |
Serruys, PW | 3 |
Peters-Krabbendam, I | 1 |
van Beusekom, HM | 1 |
Margolis, JR | 1 |
Han, Y | 1 |
Jing, Q | 1 |
Xu, B | 1 |
Yang, L | 1 |
Shang, X | 1 |
Jiang, T | 1 |
Li, Z | 1 |
Zhang, H | 1 |
Li, H | 1 |
Qiu, J | 1 |
Li, Y | 1 |
Chen, X | 1 |
Gao, R | 1 |
Maldonado, G | 1 |
Doi, H | 1 |
Maehara, A | 1 |
Mintz, GS | 4 |
Costa, Jde R | 1 |
Sano, K | 1 |
Weisz, G | 3 |
Dangas, GD | 2 |
Lansky, AJ | 4 |
Kreps, EM | 1 |
Collins, M | 1 |
Fahy, M | 1 |
Moses, JW | 7 |
Leon, MB | 7 |
Mehran, R | 3 |
Awata, M | 1 |
Nanto, S | 1 |
Uematsu, M | 1 |
Morozumi, T | 1 |
Watanabe, T | 2 |
Onishi, T | 1 |
Iida, O | 1 |
Sera, F | 1 |
Minamiguchi, H | 1 |
Kotani, J | 2 |
Nagata, S | 1 |
Otake, H | 2 |
Shite, J | 2 |
Ako, J | 1 |
Shinke, T | 2 |
Tanino, Y | 2 |
Ogasawara, D | 2 |
Sawada, T | 2 |
Miyoshi, N | 1 |
Kato, H | 1 |
Koo, BK | 3 |
Honda, Y | 2 |
Fitzgerald, PJ | 3 |
Hirata, K | 2 |
Movahed, MR | 1 |
Ruiz, M | 1 |
Cazares, M | 1 |
Pena, A | 1 |
Collet, JP | 1 |
Hulot, JS | 1 |
Silvain, J | 1 |
Barthélémy, O | 1 |
Beygui, F | 1 |
Funck-Brentano, C | 1 |
Montalescot, G | 1 |
Patel, JH | 1 |
Stoner, JA | 1 |
Owora, A | 1 |
Mathew, ST | 1 |
Thadani, U | 1 |
Gil, RJ | 1 |
Vassilev, D | 2 |
Formuszewicz, R | 1 |
Rusicka-Piekarz, T | 1 |
Doganov, A | 1 |
Sakariassen, KS | 1 |
Alberts, P | 1 |
Fontana, P | 1 |
Mann, J | 1 |
Bounameaux, H | 1 |
Sorensen, AS | 1 |
Latif, F | 1 |
Heldman, AW | 1 |
Hennebry, TA | 1 |
Cortese, B | 1 |
Picchi, A | 1 |
Micheli, A | 1 |
Furuta, T | 1 |
Yun, SC | 4 |
Seong, IW | 4 |
Lee, JH | 4 |
Lee, NH | 5 |
Cho, YH | 4 |
Cheong, SS | 1 |
Lim, DS | 2 |
Yang, JY | 1 |
Lee, SG | 2 |
Kim, KS | 1 |
Seung, KB | 1 |
Hong, TJ | 2 |
Migliorini, A | 1 |
Valenti, R | 1 |
Marcucci, R | 1 |
Parodi, G | 1 |
Giuliani, G | 1 |
Buonamici, P | 1 |
Cerisano, G | 1 |
Carrabba, N | 1 |
Gensini, GF | 1 |
Abbate, R | 1 |
Antoniucci, D | 2 |
Chhatriwalla, AK | 1 |
Gerber, RT | 1 |
Savonitto, S | 1 |
D'Urbano, M | 1 |
Caracciolo, M | 1 |
Barlocco, F | 1 |
Mariani, G | 1 |
Nichelatti, M | 1 |
Klugmann, S | 1 |
De Servi, S | 1 |
Chun, KJ | 2 |
Rhee, KS | 1 |
Chae, JK | 1 |
Ko, JK | 2 |
Park, JH | 3 |
Choi, SW | 3 |
Jeong, JO | 1 |
Jon, S | 1 |
Baber, U | 1 |
Akhter, M | 1 |
Kothari, S | 1 |
Sharma, SK | 1 |
Kini, A | 1 |
García Paredes, T | 1 |
Escudero Varela, JC | 1 |
Mora Ordóñez, JM | 1 |
Fineschi, M | 2 |
Grotti, S | 1 |
Angioli, P | 1 |
Carrera, A | 1 |
Ducci, K | 1 |
Gori, T | 2 |
Falsini, G | 1 |
Pierli, C | 1 |
Bolognese, L | 1 |
Morino, Y | 2 |
Kimura, T | 1 |
Muramatsu, T | 1 |
Ochiai, M | 1 |
Noguchi, Y | 1 |
Kato, K | 1 |
Shibata, Y | 1 |
Hiasa, Y | 1 |
Doi, O | 1 |
Yamashita, T | 1 |
Morimoto, T | 1 |
Abe, M | 1 |
Hinohara, T | 1 |
Mitsudo, K | 2 |
Serebruany, VL | 1 |
Harmsze, AM | 2 |
Robijns, K | 1 |
van Werkum, JW | 2 |
Breet, NJ | 2 |
Hackeng, CM | 2 |
Ruven, HJ | 1 |
Klungel, OH | 1 |
de Boer, A | 1 |
Deneer, VH | 2 |
Stiefelhagen, P | 1 |
Stockl, KM | 1 |
Le, L | 1 |
Zakharyan, A | 1 |
Harada, AS | 1 |
Solow, BK | 1 |
Addiego, JE | 1 |
Ramsey, S | 1 |
Larson, DM | 1 |
Duval, S | 1 |
Sharkey, SS | 1 |
Solie, C | 1 |
Tschautscher, C | 1 |
Lips, DL | 1 |
Burke, MN | 1 |
Steinhubl, S | 1 |
Henry, TD | 1 |
Sibbing, D | 2 |
Braun, S | 2 |
Morath, T | 1 |
Zeymer, U | 1 |
Zahn, R | 1 |
Senges, J | 1 |
Gitt, A | 1 |
Tiroch, KA | 1 |
Koch, W | 1 |
Roosen-Runge, T | 1 |
Chua, D | 1 |
Shalansky, SJ | 1 |
Legal, MG | 1 |
Jung, J | 1 |
Batyraliev, TA | 1 |
Fettser, DV | 1 |
Samko, AN | 1 |
Sidorenko, BA | 1 |
Venerito, M | 1 |
Kandulski, A | 1 |
Malfertheiner, P | 1 |
Cui, S | 1 |
Lü, SZ | 1 |
Chen, YD | 1 |
He, GX | 1 |
Yan, HB | 1 |
Meng, LJ | 1 |
Song, XT | 1 |
Jin, ZN | 1 |
Ge, CJ | 1 |
Percoco, G | 3 |
Monti, M | 2 |
Ferrari, F | 1 |
Zuffi, A | 1 |
Colombo, F | 2 |
Kubbajeh, M | 2 |
Arcozzi, C | 1 |
Frangione, A | 2 |
Kozuma, K | 1 |
Ota, Y | 1 |
Nagai, Y | 1 |
Katsuta, Y | 1 |
Nozaki, E | 1 |
Onodera, T | 1 |
Ikari, Y | 1 |
Kyo, E | 1 |
Yokoi, H | 1 |
Nakamura, M | 1 |
Carmignani, L | 1 |
Picozzi, S | 1 |
Stubinski, R | 1 |
Casellato, S | 1 |
Bozzini, G | 1 |
Lunelli, L | 1 |
Arena, D | 1 |
Lange, CG | 1 |
Shin, WY | 1 |
Lee, SJ | 1 |
Hyon, MS | 1 |
Bang, DW | 1 |
Choi, YJ | 2 |
Lee, BK | 2 |
Lee, K | 1 |
Park, HK | 1 |
Park, CB | 1 |
Kim, MK | 1 |
Park, WJ | 1 |
Lengenfelder, B | 1 |
Stoerk, S | 1 |
Boes, L | 1 |
Strotmann, J | 1 |
Ertl, G | 1 |
Voelker, W | 1 |
Bonz, AW | 1 |
Caixeta, A | 1 |
Parise, H | 1 |
Cristea, E | 1 |
Brodie, BR | 1 |
Witzenbichler, B | 1 |
Guagliumi, G | 3 |
Peruga, JZ | 1 |
Dudek, D | 1 |
Möeckel, M | 1 |
Alexopoulos, D | 1 |
Xanthopoulou, I | 1 |
Karantalis, V | 1 |
Mitropoulou, G | 1 |
Damelou, A | 1 |
Davlouros, P | 1 |
Camilleri, E | 1 |
Jacquin, L | 1 |
Bonello, L | 1 |
Bouman, HJ | 1 |
Bergmeijer, TO | 1 |
Ten Cate, H | 1 |
Kuliczkowski, W | 1 |
Greif, M | 1 |
Gąsior, M | 1 |
Kaczmarski, J | 1 |
Pres, D | 1 |
Poloński, L | 1 |
Bhala, N | 1 |
Taggar, JS | 1 |
Rajasekhar, P | 1 |
Banerjee, A | 1 |
Lotfi, A | 1 |
Cui, J | 1 |
Wartak, S | 1 |
Columbo, J | 1 |
Mulvey, S | 1 |
Davis, M | 1 |
Schweiger, M | 1 |
Giugliano, GR | 1 |
Yan, BP | 1 |
Ajani, AE | 5 |
Clark, DJ | 1 |
Duffy, SJ | 1 |
Andrianopoulos, N | 1 |
Brennan, AL | 1 |
Loane, P | 1 |
Reid, CM | 1 |
Vaquerizo, B | 1 |
Serra, A | 1 |
Miranda-Guardiola, F | 1 |
Martínez, V | 1 |
Antoni Gómez-Hospital, J | 1 |
Fernández, E | 1 |
Ramón Rumoroso, J | 1 |
Bosa, F | 1 |
Otaegui, I | 1 |
Katritsis, DG | 2 |
Korovesis, S | 2 |
Tzanalaridou, E | 1 |
Giazitzoglou, E | 1 |
Zografos, T | 1 |
Meier, B | 2 |
Collet, CA | 1 |
Chamié, D | 1 |
Siquera, D | 1 |
Obregon, J | 1 |
Bonaventura, K | 1 |
Sonntag, S | 1 |
Kleber, FX | 1 |
Pant, S | 1 |
Neupane, P | 1 |
Ramesh, KC | 1 |
Barakoti, M | 1 |
Pfisterer, M | 1 |
Kaiser, C | 1 |
Jeger, R | 1 |
Gwon, HC | 1 |
Hahn, JY | 1 |
Park, KW | 1 |
Song, YB | 1 |
Han, KR | 1 |
Choi, JH | 1 |
Choi, SH | 1 |
Kang, HJ | 1 |
Ahn, T | 1 |
Yoon, JH | 1 |
Chung, WY | 1 |
Hur, SH | 2 |
Jeon, DW | 1 |
Kim, BO | 1 |
Park, SH | 1 |
Jeon, HK | 1 |
Li, ZL | 1 |
Zhou, BQ | 1 |
Zhu, JH | 1 |
Fu, GS | 1 |
Bittner, HB | 1 |
Lehmann, S | 1 |
Rastan, A | 1 |
Mohr, FW | 1 |
Porto, I | 1 |
D'Amario, D | 1 |
Crea, F | 1 |
Poullis, M | 1 |
Hazan, M | 1 |
Dean, L | 1 |
Castriota, F | 1 |
Fucà, G | 1 |
Wang, P | 2 |
Zhou, S | 1 |
Zhou, R | 1 |
Liu, G | 1 |
Tang, P | 1 |
He, J | 1 |
Ma, C | 1 |
He, Y | 1 |
Yang, J | 1 |
Jeong, YH | 2 |
Park, Y | 1 |
Muse, WC | 1 |
Kwon, TJ | 1 |
Koh, JS | 1 |
Hwang, SJ | 1 |
Kwak, CH | 1 |
Hwang, JY | 1 |
Sakurai, R | 1 |
Kaneda, H | 2 |
Bonneau, HN | 2 |
Nagai, R | 1 |
Controtto, F | 1 |
Scacciatella, P | 1 |
Cristofori, R | 1 |
Grasso, C | 1 |
D'Amico, M | 1 |
Pennone, M | 1 |
Marra, S | 1 |
Jang, JS | 1 |
Jin, HY | 1 |
Seo, JS | 1 |
Yang, TH | 1 |
Kim, DK | 2 |
Kim, DS | 1 |
Seol, SH | 1 |
Kim, DI | 1 |
Cho, KI | 1 |
Kim, BH | 1 |
Park, YH | 1 |
Je, HG | 1 |
Geng, DF | 1 |
Jin, DM | 1 |
Wu, W | 1 |
Deng, J | 1 |
Wang, JF | 1 |
Einecke, D | 1 |
Brodie, B | 1 |
Pokharel, Y | 1 |
Garg, A | 1 |
Kissling, G | 1 |
Hansen, C | 1 |
Milks, S | 1 |
Cooper, M | 1 |
McAlhany, C | 1 |
Stuckey, T | 1 |
Kim, JM | 1 |
Park, DS | 1 |
Lee, KH | 1 |
Sim, DS | 1 |
Yoon, HJ | 1 |
Yoon, NS | 1 |
Kim, KH | 2 |
Park, HW | 1 |
Ahn, Y | 2 |
Cho, JG | 1 |
Park, JC | 1 |
Kang, JC | 1 |
Itagaki, BK | 1 |
Brar, SS | 1 |
Pinnow, E | 2 |
Cheneau, E | 2 |
Leborgne, L | 2 |
Dieble, R | 1 |
Bui, AB | 1 |
Satler, LF | 4 |
Pichard, AD | 3 |
Kent, KK | 1 |
Lindsay, J | 2 |
Kamishirado, H | 1 |
Inoue, T | 2 |
Mizoguchi, K | 1 |
Uchida, T | 2 |
Nakata, T | 1 |
Sakuma, M | 2 |
Takayanagi, K | 1 |
Morooka, S | 1 |
Silber, S | 4 |
Talbert, RL | 1 |
Spinler, SA | 3 |
Nappi, JM | 1 |
Bottorff, MB | 1 |
Krötz, F | 1 |
Schiele, TM | 1 |
Zahler, S | 1 |
König, A | 1 |
Rieber, J | 1 |
Kantlehner, R | 1 |
Pöllinger, B | 1 |
Dühmke, E | 1 |
Theisen, K | 1 |
Sohn, HY | 1 |
Klauss, V | 1 |
Ziegler, S | 1 |
Maca, T | 1 |
Alt, E | 1 |
Speiser, W | 1 |
Schneider, B | 1 |
Minar, E | 1 |
Sick, P | 1 |
Hüttl, T | 1 |
Niebauer, J | 2 |
Thiele, H | 2 |
Lauer, B | 1 |
Hambrecht, R | 1 |
Hentschel, B | 1 |
Schuler, G | 2 |
Wohlgemuth, WA | 1 |
Bohndorf, K | 1 |
Baumgart, D | 1 |
Hehrlein, C | 1 |
Meinertz, T | 1 |
Mügge, A | 1 |
Rutsch, W | 2 |
vom Dahl, J | 1 |
Toutouzas, K | 1 |
Di Mario, C | 4 |
Falotico, R | 1 |
Takagi, T | 1 |
Stankovic, G | 1 |
Albiero, R | 1 |
Corvaja, N | 1 |
Fujita, M | 1 |
Mizuno, K | 1 |
Ho, M | 1 |
Tsukahara, R | 1 |
Miyamoto, A | 1 |
Miki, O | 1 |
Ishii, K | 1 |
Miwa, K | 1 |
Shim, WH | 1 |
Ho, DS | 1 |
Raizner, AE | 2 |
Choi, D | 1 |
Lam, R | 1 |
Weissman, NJ | 1 |
Cha, DH | 1 |
Malik, IA | 1 |
Wolfram, R | 1 |
Porrazzo, M | 1 |
Kent, KM | 1 |
Bass, TA | 1 |
Tani, S | 1 |
Kanmatsuse, K | 1 |
Bouvier, JL | 1 |
Roquebert, PO | 1 |
Macaluso, G | 1 |
Commeau, P | 1 |
Comet, B | 1 |
Lafont, A | 1 |
Camoin, L | 1 |
Walter, U | 1 |
Eigenthaler, M | 2 |
Grise, MA | 1 |
Reilly, JP | 1 |
Tobis, JM | 1 |
Takano, Y | 1 |
Currier, JW | 1 |
Kobashigawa, JA | 1 |
Yeung, A | 1 |
Teirstein, PS | 3 |
Pekdemir, H | 1 |
Cin, VG | 1 |
Camsari, A | 1 |
Cicek, D | 1 |
Akkus, MN | 1 |
Doven, O | 1 |
Parmaksiz, T | 1 |
Schühlen, H | 4 |
Dotzer, F | 3 |
Bollwein, H | 3 |
Volmer, C | 1 |
Gawaz, M | 1 |
Berger, PB | 3 |
Jaster, M | 1 |
Fuster, V | 1 |
Pauschinger, M | 1 |
Tran, QV | 1 |
Janssen, D | 1 |
Hinkelbein, W | 1 |
Schwimmbeck, P | 1 |
Khambekar, SK | 1 |
Kovac, J | 1 |
Gershlick, AH | 3 |
Song, JM | 1 |
Han, KH | 2 |
Kang, DH | 1 |
Song, JK | 1 |
Topol, EJ | 4 |
Ludwig, J | 1 |
Holmes, DR | 4 |
Spanos, V | 1 |
Louvard, Y | 2 |
Desmedt, B | 1 |
Von Scheidt, W | 1 |
Gurbel, PA | 2 |
Samara, WM | 1 |
Bliden, KP | 1 |
Matetzky, S | 1 |
Shenkman, B | 1 |
Guetta, V | 1 |
Shechter, M | 1 |
Beinart, R | 1 |
Bienart, R | 1 |
Goldenberg, I | 1 |
Novikov, I | 1 |
Pres, H | 1 |
Savion, N | 1 |
Varon, D | 1 |
Hod, H | 1 |
SoRelle, R | 1 |
Sekiguchi, M | 1 |
Hoshizaki, H | 1 |
Adachi, H | 1 |
Ohshima, S | 1 |
Taniguchi, K | 1 |
Kurabayashi, M | 1 |
Hashiguchi, M | 1 |
Ohno, K | 1 |
Nakazawa, R | 1 |
Kishino, S | 1 |
Mochizuki, M | 1 |
Shiga, T | 1 |
Sawhney, N | 1 |
Kuntz, RE | 4 |
Popma, JJ | 5 |
Bachinsky, W | 1 |
Bass, T | 1 |
DeMaio, S | 1 |
Fry, E | 1 |
Cohen, DJ | 2 |
Bakhai, A | 1 |
Shi, C | 1 |
Githiora, L | 1 |
Lavelle, T | 1 |
Berezin, RH | 1 |
Carrozza, JP | 1 |
Zidar, JP | 1 |
Vivekananthan, DP | 1 |
Chew, DP | 1 |
Zidar, FJ | 1 |
Chan, AW | 1 |
Moliterno, DJ | 2 |
Ellis, SG | 2 |
Casselman, FP | 1 |
Meco, M | 1 |
Dom, H | 1 |
Foubert, L | 1 |
Van Praet, F | 1 |
Vanermen, H | 1 |
Weintraub, WS | 1 |
Brener, SJ | 2 |
Lincoff, AM | 1 |
Steinhubl, SR | 2 |
Wolski, KE | 1 |
Akbulut, M | 1 |
Ozbay, Y | 1 |
Karaca, I | 1 |
Ilkay, E | 1 |
Gundogdu, O | 1 |
Arslan, N | 1 |
Sianos, G | 2 |
de Scheerder, I | 1 |
van den Heuvel, PA | 1 |
Glogar, HD | 1 |
Materne, PH | 1 |
Veldhof, S | 1 |
Vonhausen, H | 1 |
Otto-Terlouw, PC | 1 |
Rampp, T | 1 |
Block, M | 1 |
Ohman, EM | 1 |
Harrington, RA | 1 |
Grines, C | 1 |
Weitz, JI | 1 |
Imoto, Y | 1 |
Ozeki, Y | 1 |
Ozaki, Y | 2 |
Hikichi, Y | 1 |
Node, K | 1 |
Melero, JM | 1 |
Porras, C | 1 |
Such, M | 1 |
Olalla, E | 1 |
Alonso, J | 1 |
Dibra, A | 2 |
von Beckerath, N | 1 |
Berger, PP | 1 |
Cox, N | 1 |
Fitzpatrick, M | 1 |
Douglas, J | 1 |
Lambert, C | 1 |
Mooney, M | 1 |
Yakubov, S | 1 |
von Mach, MA | 1 |
Eich, A | 1 |
Weilemann, LS | 1 |
Münzel, T | 1 |
Nikfardjam, M | 1 |
Huber-Beckmann, R | 1 |
Gottsauner-Wolf, M | 1 |
Glogar, D | 2 |
Binder, BR | 1 |
Wojta, J | 2 |
Huber, K | 2 |
Maresta, A | 2 |
Balducelli, M | 1 |
Latini, R | 1 |
Bernardi, G | 1 |
Moccetti, T | 1 |
Sosa, C | 1 |
Barlera, S | 1 |
Varani, E | 2 |
Ribeiro da Silva, EE | 1 |
Monici Preti, A | 1 |
Maggioni, AP | 1 |
von Heymann, C | 1 |
Schoenfeld, H | 1 |
Sander, M | 1 |
Ziemer, S | 1 |
Grubitzsch, H | 1 |
Spies, C | 1 |
Karvouni, E | 1 |
Mehta, RH | 1 |
Harjai, KJ | 1 |
Boura, J | 1 |
O'Neill, W | 1 |
Benito, B | 1 |
Masotti, M | 1 |
Betriu, A | 1 |
Sick, PB | 1 |
Brosteanu, O | 1 |
Ulrich, M | 1 |
Busch, I | 1 |
Hadamitzky, M | 1 |
Baum, H | 1 |
Biancari, F | 1 |
Juvonen, T | 1 |
Chen, WH | 1 |
Kaul, U | 1 |
Leung, SK | 1 |
Lau, YK | 1 |
Tan, HC | 1 |
Leung, AW | 1 |
Lee, MK | 1 |
Li, SK | 1 |
Ng, W | 1 |
Lee, PY | 1 |
Lam, KF | 1 |
Tse, HF | 1 |
Lau, CP | 1 |
Suzuki, J | 1 |
Hosokawa, G | 1 |
Tanaka, S | 1 |
Hiroe, Y | 1 |
Saito, S | 1 |
Lengyel, M | 1 |
Bull, S | 1 |
Chahal, N | 1 |
McKenna, CJ | 1 |
Kramer, HJ | 1 |
Tepe, G | 1 |
Muschick, P | 1 |
Laule, M | 1 |
Reddig, F | 1 |
Claussen, CD | 1 |
Dinkelborg, LM | 1 |
Tielemans, H | 1 |
Wehrmann, M | 1 |
Duda, SH | 1 |
Biondi-Zoccai, GG | 1 |
Agostoni, P | 1 |
Iakovou, I | 1 |
Grube, E | 2 |
Reimers, B | 2 |
Goktekin, O | 1 |
Tassanawiwat, W | 1 |
Kurşaklioğlu, H | 1 |
Köz, C | 1 |
Ide, T | 1 |
Yildirim, V | 1 |
Töre, HF | 1 |
Demirtaş, E | 1 |
Urban, P | 1 |
Guyon, P | 1 |
Lotan, C | 1 |
Schofer, J | 2 |
Seth, A | 1 |
Berge, C | 1 |
Deme, M | 1 |
Stoll, HP | 1 |
Templin, C | 1 |
Schaefer, A | 1 |
Stumme, B | 1 |
Drexler, H | 1 |
von Depka, M | 1 |
Makkar, K | 1 |
Wilensky, RL | 3 |
Julien, MB | 1 |
Herrmann, HC | 1 |
Lee-Wong, M | 1 |
Gadhvi, D | 1 |
Resnick, D | 1 |
Spertus, JA | 1 |
Kettelkamp, R | 1 |
Vance, C | 1 |
Decker, C | 1 |
Jones, PG | 1 |
Rumsfeld, JS | 1 |
Messenger, JC | 1 |
Khanal, S | 1 |
Peterson, ED | 1 |
Bach, RG | 1 |
Krumholz, HM | 1 |
Hausleiter, J | 1 |
Ishikawa, T | 2 |
Mutoh, M | 2 |
Fuda, Y | 2 |
Sakamoto, H | 2 |
Okada, H | 2 |
Higashitani, M | 2 |
Nakano, Y | 2 |
Yamaguchi, J | 1 |
Enta, K | 1 |
Satoh, T | 1 |
Imai, K | 2 |
Horie, T | 2 |
Mochizuki, S | 2 |
Nikas, DN | 1 |
Kalef-Ezra, J | 1 |
Katsouras, CS | 1 |
Tsekeris, P | 1 |
Bozios, G | 1 |
Pappas, C | 1 |
Naka, KK | 1 |
Kotsia, A | 1 |
Papamichael, N | 1 |
Sideris, DA | 1 |
Michalis, LK | 1 |
Gruberg, L | 1 |
Beyar, R | 1 |
Tantry, US | 1 |
Gaku, N | 1 |
Kengo, T | 1 |
Aoki, J | 1 |
Onuma, Y | 1 |
Yamamoto, H | 1 |
Higashikuni, Y | 1 |
Nakajima, H | 1 |
Hara, K | 1 |
McAllister, RK | 1 |
Dehmer, GJ | 1 |
Meyer, TA | 1 |
Tsurusaki, T | 1 |
Ohta, M | 1 |
Broad, L | 1 |
Lee, T | 1 |
Conroy, M | 1 |
Bolsin, S | 1 |
Orford, N | 1 |
Black, A | 1 |
Birdsey, G | 1 |
Matsumoto, D | 1 |
Paredes, OL | 1 |
Yokoyama, M | 1 |
Gochi, T | 1 |
Umeda, H | 1 |
Yoshida, N | 1 |
Maekawa, H | 1 |
Watanabe, K | 1 |
Okada, T | 1 |
Katoh, T | 1 |
Asai, T | 1 |
Tani, T | 1 |
Yokoya, M | 1 |
Murakami, Y | 1 |
Matsushita, T | 1 |
Shimizu, T | 1 |
Hiramitsu, S | 1 |
Murohara, T | 1 |
Nomura, M | 1 |
Morimoto, S | 1 |
Hishida, H | 1 |
Richardson, G | 1 |
Wiper, AJ | 1 |
Roberts, DH | 1 |
Antoniou, S | 1 |
Rothman, MT | 1 |
Wenaweser, P | 1 |
Billinger, M | 1 |
Cook, S | 1 |
Togni, M | 1 |
Haeberli, A | 1 |
Hess, OM | 1 |
Schäfer, A | 1 |
Bauersachs, J | 1 |
Rabbat, MG | 1 |
Bavry, AA | 1 |
Eltchaninoff, H | 1 |
Funck, F | 1 |
Grinius, V | 1 |
Navickas, R | 1 |
Unikas, R | 1 |
Daemen, J | 1 |
Tanimoto, S | 1 |
García-García, HM | 1 |
Kukreja, N | 1 |
van de Sande, M | 1 |
de Jaegere, PP | 1 |
van Domburg, RT | 1 |
Mishkel, G | 1 |
Bartorelli, AL | 1 |
Trabattoni, D | 1 |
Galassi, A | 1 |
Serdoz, R | 1 |
Sheiban, I | 1 |
Piovaccari, G | 2 |
Zimarino, M | 1 |
Benassi, A | 2 |
Sangiorgio, P | 1 |
Chierchia, S | 1 |
Finn, AV | 1 |
Joner, M | 1 |
Nakazawa, G | 1 |
Kolodgie, F | 1 |
Newell, J | 1 |
John, MC | 1 |
Gold, HK | 1 |
Virmani, R | 1 |
Hacquard, M | 1 |
Angioï, M | 1 |
Lecompte, T | 1 |
Vigneron, C | 1 |
Tamura, A | 1 |
Shinozaki, K | 1 |
Kotoku, M | 1 |
Yano, S | 1 |
Kadota, J | 1 |
Majdoub, MA | 1 |
Sauguet, A | 1 |
Tchetche, D | 1 |
Ducrocq, G | 1 |
Himbert, D | 1 |
Aubry, P | 1 |
Feldman, LJ | 1 |
Juliard, JM | 1 |
Gladding, P | 1 |
Webster, M | 1 |
Angiolillo, DJ | 1 |
Hernández-Antolín, R | 1 |
SanMartín, M | 1 |
Gómez-Hospital, JA | 1 |
Moreno, R | 1 |
Fernández, C | 1 |
Fernández-Avilés, F | 1 |
Marzocchi, A | 1 |
Saia, F | 1 |
Manari, A | 1 |
Aurier, E | 1 |
Cremonesi, A | 1 |
Magnavacchi, P | 1 |
Guastaroba, P | 1 |
Grilli, R | 1 |
Hoppe, UC | 1 |
Erdmann, E | 1 |
Brennan, DM | 1 |
Asamasu-Sato, S | 1 |
Mita, M | 1 |
Ogawa, R | 1 |
Isaka, M | 1 |
Saito, M | 1 |
Jang, S | 1 |
Chi, HS | 1 |
Unverdorben, M | 1 |
Degenhardt, R | 1 |
Wiemer, M | 1 |
Horstkotte, D | 1 |
Schneider, H | 1 |
Nienaber, C | 1 |
Bocksch, W | 1 |
Gross, M | 1 |
Boxberger, M | 1 |
Vallbracht, C | 1 |
Roy, P | 1 |
Torguson, R | 1 |
Okabe, T | 1 |
Pinto Slottow, TL | 1 |
Steinberg, DH | 1 |
Smith, K | 1 |
Xue, Z | 1 |
Dawkins, KD | 1 |
Banning, AP | 2 |
Zmudka, K | 1 |
Thuesen, L | 1 |
Hauptman, K | 1 |
Marco, J | 1 |
Buellesfeld, L | 1 |
Koglin, J | 1 |
Russell, ME | 1 |
Mood, GR | 1 |
Bhatia, A | 1 |
Nicholls, H | 1 |
Jeong, JW | 1 |
Ahn, TH | 1 |
Kang, WC | 1 |
Park, CG | 1 |
Nam, CW | 1 |
Bae, JH | 1 |
Kim, KY | 1 |
Oh, SK | 1 |
Katsaros, KM | 1 |
Speidl, WS | 1 |
Kastl, SP | 1 |
Zorn, G | 1 |
Maurer, G | 1 |
Sheehy, O | 1 |
LeLorier, J | 1 |
Rinfret, S | 1 |
Suissa, S | 1 |
Ryding, AD | 1 |
Bertrand, OF | 1 |
Faurie, B | 1 |
Larose, E | 1 |
Nguyen, CM | 1 |
Gleeton, O | 1 |
Déry, JP | 1 |
Noël, B | 1 |
Proulx, G | 1 |
Roy, L | 1 |
Costerousse, O | 1 |
De Larochellière, R | 1 |
Rodés-Cabau, J | 1 |
Krucoff, MW | 1 |
Petersen, JL | 1 |
Hasselblad, V | 1 |
Garg, J | 1 |
Turco, MA | 1 |
Simonton, CA | 1 |
Verheye, S | 1 |
Dubois, CL | 1 |
Gammon, R | 1 |
Batchelor, WB | 1 |
O'Shaughnessy, CD | 1 |
Hermiller, JB | 1 |
Buchbinder, M | 1 |
Ndrepepa, G | 1 |
Hutten, BA | 1 |
Kelder, JC | 1 |
Verheugt, FW | 1 |
Plokker, HW | 1 |
Dzavik, V | 1 |
Penn, IM | 1 |
Catellier, D | 1 |
Buller, CE | 1 |
Makoni, SN | 1 |
Limpijankit, T | 1 |
Yock, PG | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
Short-term Outcomes of Elective High-risk PCI With Extracorporeal Membrane Oxygenation Support: a Single-centre Registry[NCT05387902] | 25 participants (Actual) | Observational [Patient Registry] | 2022-02-03 | Completed | |||
A Trial of Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients With Long or Multi-vessel Coronary Artery Disease Underwent Biolimus-Eluting Stent Implantation[NCT01192724] | Phase 4 | 630 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial[NCT00476957] | Phase 4 | 8,709 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044] | 120 participants (Anticipated) | Interventional | 2015-11-30 | Active, not recruiting | |||
Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial[NCT01476020] | 1,240 participants (Anticipated) | Observational | 2011-11-30 | Not yet recruiting | |||
Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study[NCT01385319] | Phase 3 | 1,606 participants (Actual) | Interventional | 2011-06-30 | Active, not recruiting | ||
A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment[NCT02294643] | Phase 3 | 220 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients[NCT01866904] | 9,284 participants (Actual) | Observational | 2013-06-19 | Terminated (stopped due to Study was terminated in order to secure the data quality of the study in terms of follow-up rates and data completeness.) | |||
Prospective Study of Bioresorbable Vascular Scaffold Treatment With Scoring Balloon Pre-dilatation in Patients With In-stent Restenosis[NCT03069066] | Phase 4 | 100 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial[NCT01239953] | Phase 4 | 190 participants (Actual) | Interventional | 2010-01-31 | Active, not recruiting | ||
RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial[NCT01239940] | Phase 4 | 310 participants (Anticipated) | Interventional | 2010-01-31 | Recruiting | ||
Prospective Study of Bioresorbable Vascular Scaffold Treatment in Patients With In-stent Restenosis[NCT02672878] | Phase 4 | 130 participants (Anticipated) | Interventional | 2014-04-30 | Not yet recruiting | ||
Observational Study of Treatment of Bioresorbable Vascular Scaffolds Restenosis[NCT03167424] | 100 participants (Anticipated) | Observational [Patient Registry] | 2016-05-31 | Recruiting | |||
Platelet Function in Resuscitated Patients[NCT02914795] | 99 participants (Actual) | Observational | 2015-06-30 | Completed | |||
The SOS (Stenting Of Saphenous Vein Grafts) Randomized-controlled Trial of a Paclitaxel-eluting Stent vs. a Bare Metal Stent in Saphenous Vein Graft Lesions[NCT00247208] | Phase 3 | 80 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
Prospective, Randomized Trial of the Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease(ISAR-LEFT-MAIN)[NCT00133237] | Phase 4 | 607 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent[NCT00331578] | Phase 4 | 2,077 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
Regular DES Versus BiOSS Expert® Stent in Coronary Bifurcation Treatment - Randomized, Multicenter, Open-label, Controlled POLBOS I (POLish Bifurcation Optimal Stenting) Study[NCT02192840] | Phase 4 | 243 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
A Prospective Single Arm Clinical Trial Evaluating the MitraClip System in Australia and New Zealand[NCT01301625] | 78 participants (Actual) | Observational | 2011-11-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
Comparison of Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent Implantation For Long Coronary Lesions[NCT00589927] | Phase 4 | 486 participants (Anticipated) | Interventional | 2007-12-31 | Completed | ||
Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary An[NCT00433966] | Phase 3 | 3,602 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)[NCT00352014] | 1,000 participants (Anticipated) | Observational | 2006-01-31 | Completed | |||
Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions[NCT00698607] | Phase 4 | 1,466 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
LAte Stent Strut APPosition and COverage After Drug-Eluting Stent ImplantaTIOn by Optical Coherence Tomography in PatieNts With Acute Myocardial Infarction II(APPOSITION-AMI II)[NCT02770651] | 69 participants (Anticipated) | Observational | 2016-05-31 | Enrolling by invitation | |||
Risk Stratification for Subclinical Leaflet Thrombosis Post TAVI Using Thromboelastography[NCT03649594] | 100 participants (Anticipated) | Observational | 2020-10-01 | Recruiting | |||
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)[NCT00133003] | Phase 4 | 2,022 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3[NCT00262054] | Phase 4 | 4,570 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)[NCT00133250] | Phase 4 | 800 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465] | Phase 4 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428] | 159 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802] | 120 participants (Anticipated) | Interventional | 2014-08-31 | Not yet recruiting | |||
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT00697372] | Phase 4 | 150 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions)[NCT01278186] | Phase 4 | 190 participants (Anticipated) | Interventional | 2010-06-30 | Active, not recruiting | ||
Prospective, Randomized, Single-Center Evaluation of the Cypher™ Sirolimus Eluting Coronary Stent System in the Treatment of Bifurcated Coronary Lesions[NCT00288535] | Phase 4 | 200 participants (Anticipated) | Interventional | 2005-03-31 | Recruiting | ||
Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation[NCT00905671] | Phase 4 | 20 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT01200693] | Phase 4 | 80 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612] | Phase 3 | 200 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301] | 100 participants (Anticipated) | Observational | 2015-09-30 | Not yet recruiting | |||
Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044] | Phase 3 | 30 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | ||
Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.[NCT00552669] | Phase 4 | 200 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
ABILITY Diabetes Global[NCT04236609] | 3,050 participants (Actual) | Interventional | 2020-06-15 | Active, not recruiting | |||
Spot Drug-Eluting vs Full Cover Stenting for Long Coronary Stenoses: a Randomized Clinical Study[NCT00738556] | 179 participants (Actual) | Interventional | 2003-01-31 | Completed | |||
[NCT00000614] | Phase 3 | 0 participants | Interventional | 1998-09-30 | Completed | ||
Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients[NCT01261273] | 18,000 participants (Actual) | Observational | 2010-08-25 | Completed | |||
BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With de Novo Coronary Artery Lesions-VI[NCT02870985] | Phase 3 | 440 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications (The Nudge Study)[NCT03973931] | 9,501 participants (Actual) | Interventional | 2019-07-01 | Active, not recruiting | |||
Activity of Platelets After Inhibition and Cardiovascular Events: Drug Eluting Stent Implantation in Patients With Acute Coronary Syndrome: Optical Coherence Tomography Study[NCT01239654] | Phase 3 | 60 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease[NCT00704145] | Phase 4 | 30 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography[NCT00693030] | Phase 4 | 77 participants (Anticipated) | Interventional | 2006-08-31 | Recruiting | ||
The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)[NCT00776204] | 60 participants (Actual) | Interventional | 2008-05-31 | Completed | |||
Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve[NCT02384837] | 33 participants (Actual) | Observational | 2014-12-31 | Completed | |||
Prospective, Randomized, Controlled Arm Study Comparing the Coverage of the Zotarolimus-eluting Stent vs Bare Metal Stent Implanted in ST- Elevation Myocardial Infarction (STEMI).[NCT00704561] | 44 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study[NCT01742507] | Phase 4 | 60 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465] | Phase 4 | 50 participants (Actual) | Interventional | 2017-02-16 | Completed | ||
Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement[NCT01219894] | 0 participants (Actual) | Observational | 2010-11-30 | Withdrawn (stopped due to Number of patients to meet individual IDE requirements was not obtained.) | |||
Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)[NCT01794949] | 8 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
Multi-Center, Single-Blind, Two-Arm, Randomized, Controlled, Non Inferiority Trial of the Conor CoStar Paclitaxel-Eluting Coronary Stent System vs the TAXUS DES in Patients With De Novo Lesions of the Native Coronary Arteries[NCT00165035] | Phase 3 | 1,701 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Definite or probable stent thrombosis rate. (NCT00476957)
Timeframe: 3 years
Intervention | participants (Number) |
---|---|
E-ZES | 61 |
C-SES | 75 |
Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions (NCT00476957)
Timeframe: 3 years
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Total death and large non-fatal myocardial infarct | Total death and non-fatal myocardial infarctions | Cardiac death and large non-fatal MI | Cardiac death and non-fatal MI | Target lesion revascularization | Stroke | Bleeding events | |
C-SES | 255 | 360 | 174 | 282 | 156 | 72 | 184 |
E-ZES | 225 | 331 | 157 | 265 | 249 | 77 | 201 |
(NCT00228423)
Timeframe: 1 year
Intervention | Participants (Count of Participants) |
---|---|
75mg Clopidogrel | 4 |
Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
Intervention | Participants (Count of Participants) |
---|---|
75mg Clopidogrel | 1 |
Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
Intervention | percentage (Number) |
---|---|
75mg Clopidogrel | 94.3 |
Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
Intervention | mm (Mean) |
---|---|
75mg Clopidogrel | 4.1 |
Placebo | 4.5 |
(NCT02914795)
Timeframe: 7 days
Intervention | Participants (Count of Participants) |
---|---|
Non-resuscitated Myocardial Infarction | 0 |
Resuscitated Myocardial Infarction | 3 |
Median (Inter-Quartile Range) Collagen AUC values on Day 3 measured with optical aggregometry The more light signal is detected, the better thrombocyte function is. (NCT02914795)
Timeframe: day 3
Intervention | AU*min (Median) |
---|---|
Non-resuscitated Myocardial Infarction | 109 |
Resuscitated Myocardial Infarction | 253.8 |
This is one of the Device and Procedure-Related Endpoints. Device Time is defined as the time the Steerable Guide Catheter is placed in the intra-atrial septum until the time the MitraClip Delivery System (CDS) is retracted into the Steerable Guide Catheter. Device Time is shorter in duration than Procedure Time because it does not include the time required to perform transseptal access into the left atrium. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
Intervention | Minutes (Mean) |
---|---|
MitraClip Implant | 91.2 |
This is one of the Device and Procedure-Related Endpoints. Mean fluoroscopy duration during the MitraClip procedure. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
Intervention | Minutes (Mean) |
---|---|
MitraClip Implant | 41.2 |
Defined as successful MitraClip implantation with resulting MR of 2+ or less. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
Intervention | Participants (Count of Participants) |
---|---|
MitraClip Implant | 39 |
"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 12 months
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 8.3 |
"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 30 days
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 0.0 |
"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 6 months
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 6.1 |
"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: Baseline
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 0.0 |
"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded. B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 6 months
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 91.5 |
"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 12 months
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 85.3 |
"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 30 days
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 96.1 |
"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: Baseline
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 100 |
This is the Economic data reported to support the MitraClip System economic analysis. It is defined as the mean duration of time that patients spent in hospital following the MitraClip procedure. (NCT01301625)
Timeframe: Post index procedure within 30 days
Intervention | Days (Mean) |
---|---|
MitraClip Implant | 3.4 |
ICU and hospital stay is defined as the mean duration of time that patients spent in the ICU (Intensive Care Unit)/ CCU (Cardiac Care Unit)/ PACU (Post-Anesthesia Care Unit) following the MitraClip procedure. (NCT01301625)
Timeframe: Post index procedure within 30 days
Intervention | Hours (Mean) |
---|---|
MitraClip Implant | 62.1 |
This is one of the Device and Procedure-Related Endpoints. Procedure Time is defined as the time elapsed from the start of the transseptal procedure to the time the Steerable Guide Catheter is removed. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
Intervention | Minutes (Mean) |
---|---|
MitraClip Implant | 133.5 |
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 12 months
Intervention | Meters (Mean) |
---|---|
MitraClip Implant | 329.9 |
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 30 days
Intervention | Meters (Mean) |
---|---|
MitraClip Implant | 297.3 |
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 6 months
Intervention | Meters (Mean) |
---|---|
MitraClip Implant | 324.3 |
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: Baseline
Intervention | Meters (Mean) |
---|---|
MitraClip Implant | 271.0 |
This is one of the Device and Procedure-Related Endpoints. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
Intervention | Milliliters (Mean) |
---|---|
MitraClip Implant | 10.6 |
"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 12 months
Intervention | scores on a scale (Mean) | ||
---|---|---|---|
Baseline | 12 months | Difference (12 months - Baseline) | |
MitraClip Implant | 51.1 | 30.2 | -20.9 |
"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 30 days
Intervention | scores on a scale (Mean) | ||
---|---|---|---|
Baseline | 30 days | Difference (30 days - Baseline) | |
MitraClip Implant | 50.4 | 26.4 | -24.0 |
"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 6 months
Intervention | scores on a scale (Mean) | ||
---|---|---|---|
Baseline | 6 months | Difference (6 months - Baseline) | |
MitraClip Implant | 49.5 | 28.0 | -21.5 |
(NCT01301625)
Timeframe: 30 days
Intervention | Days (Mean) | |||
---|---|---|---|---|
All re-hospitalizations | Heart Failure-related re-hospitalizations | Other cardiac-related re-hospitalizations | Other non-cardiac-related re-hospitalizations | |
MitraClip Implant | 8.4 | 18.38 | 2.87 | 7.44 |
Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and 12 Months
Intervention | ml (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 148.5 | 132.4 |
Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | ml (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 140.4 | 138.8 |
Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | ml (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 141.7 | 141.8 |
Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 12 months
Intervention | ml (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 161.1 | 150.1 |
Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | ml (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 152.9 | 148.2 |
Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | Milliliters (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 158.2 | 151.3 |
Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and 12 months
Intervention | percent (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 46.9 | 47.4 |
Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | percent (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 48.4 | 46.5 |
Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | percent (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 47.2 | 44.6 |
Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 12 months
Intervention | ml (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 97.8 | 91.7 |
Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | ml (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 88.5 | 89.0 |
Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | Milliliter (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 93.3 | 93.2 |
LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months
Intervention | cm (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 6.0 | 5.7 |
LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | cm (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 5.9 | 5.7 |
LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | cm (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 5.9 | 5.7 |
LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months
Intervention | cm (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 4.6 | 4.5 |
LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | cm (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 4.5 | 4.5 |
LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | cm (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 4.5 | 4.4 |
Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months
Intervention | cm^2 (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 3.8 | 2.3 |
Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | cm^2 (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 3.5 | 2.3 |
Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | cm^2 (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 3.5 | 2.4 |
Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and 12 Months
Intervention | mmHg (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 2.3 | 3.4 |
Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | mmHg (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 2.3 | 3.5 |
Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | mmHg (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 2.3 | 3.7 |
This is the economic data reported to support the MitraClip System economic analysis. (NCT01301625)
Timeframe: < or = 12 days
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
Home | Home with home health care | Skilled nursing facility | Nursing home | Death | Other | |
MitraClip Implant | 70 | 4 | 1 | 0 | 2 | 1 |
This is one of the Device and Procedure-Related Endpoints. Implant Rate is defined as the rate of successful delivery and deployment of MitraClip device implant(s) with echocardiographic evidence of leaflet approximation and retrieval of the delivery catheter. (NCT01301625)
Timeframe: Day 0 (On the day of procedure)
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
0 Mitra Clip devices | 1 Mitra Clip devices | 2 Mitra Clip devices | 3 Mitra Clip devices | |
MitraClip Implant | 1 | 41 | 35 | 1 |
Mital Valve Surgery Post-MitraClip Procedure; Surgery Types includes Replacement and Repair. (NCT01301625)
Timeframe: 30 days of Post-MitraClip Procedure
Intervention | Participants (Count of Participants) | |
---|---|---|
Recurring mitral regurgitation | Device failure | |
MitraClip Implant | 1 | 1 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 12 months
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
MitraClip Implant | 2 | 15 | 15 | 7 | 3 | 0 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 30 days
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
MitraClip Implant | 1 | 26 | 25 | 12 | 5 | 0 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 6 months
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
MitraClip Implant | 0 | 20 | 24 | 12 | 4 | 0 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: At discharge (≤7 days of index procedure)
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
MitraClip Implant | 1 | 38 | 22 | 9 | 3 | 1 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: Baseline
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
MitraClip Implant | 0 | 0 | 0 | 22 | 55 | 0 |
Second MitraClip device interventions are reported by Abbott Vascular personnel on Procedural Observation Forms. A second MitraClip device intervention is a good option for patients with MR following placement of the original MitraClip device. (NCT01301625)
Timeframe: Through 12 months
Intervention | Participants (Count of Participants) | |
---|---|---|
Recurring mitral regurgitation | Single leaflet device attachment (SLDA) | |
MitraClip Implant | 2 | 1 |
"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 12 months
Intervention | percentage of participants (Number) | |||
---|---|---|---|---|
NYHA I | NYHA II | NYHA III | NYHA IV | |
MitraClip Implant | 52.5 | 42.5 | 2.5 | 2.5 |
"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 30 days
Intervention | percentage of participants (Number) | |||
---|---|---|---|---|
NYHA I | NYHA II | NYHA III | NYHA IV | |
MitraClip Implant | 36.2 | 44.9 | 15.9 | 2.9 |
"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 6 months
Intervention | percentage of participants (Number) | |||
---|---|---|---|---|
NYHA I | NYHA II | NYHA III | NYHA IV | |
MitraClip Implant | 33.3 | 56.7 | 8.3 | 1.7 |
"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: Baseline
Intervention | percentage of participants (Number) | |||
---|---|---|---|---|
NYHA I | NYHA II | NYHA III | NYHA IV | |
MitraClip Implant | 2.6 | 26.9 | 51.3 | 19.2 |
Defined as re-admission of patients to the hospital following discharge from the Clip procedure. (NCT01301625)
Timeframe: 30 days
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
All re-hospitalizations | Heart Failure-related re-hospitalizations | Other cardiac-related re-hospitalizations | Other non-cardiac-related re-hospitalizations | |
MitraClip Implant | 35 | 10 | 11 | 22 |
Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and 12 Months
Intervention | Percentage (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 44.6 | 36.8 |
Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | Percentage (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 40.5 | 15.2 |
Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | Percentage (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 38.9 | 25.8 |
Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and 12 Months
Intervention | ml (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 49.8 | 73.3 |
Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | ml (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 61.9 | 25.6 |
Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | ml (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 55.5 | 25.1 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 3 years
Intervention | Participants (Count of Participants) |
---|---|
Pharmacology Arm - Bivalirudin | 379 |
Pharmacology Arm - Unfractionated Heparin | 377 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 30 days
Intervention | Participants (Count of Participants) |
---|---|
Pharmacology Arm - Bivalirudin | 98 |
Pharmacology Arm - Unfractionated Heparin | 99 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) and major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting). (NCT00433966)
Timeframe: 30 Days
Intervention | Participants (Count of Participants) |
---|---|
Pharmacology Arm - Bivalirudin | 166 |
Pharmacology Arm - Unfractionated Heparin | 218 |
Number of participants with major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting) (NCT00433966)
Timeframe: 30 days
Intervention | Participants (Count of Participants) |
---|---|
Pharmacology Arm - Bivalirudin | 89 |
Pharmacology Arm - Unfractionated Heparin | 149 |
Number of Participants With Death, Reinfarction, Stroke, or Stent Thrombosis (NCT00433966)
Timeframe: 1 year
Intervention | Participants (Count of Participants) |
---|---|
Stent Arm - Paclitaxel-Eluting Stent | 181 |
Stent Arm - Bare Metal Stent | 59 |
Number of Participants With Ischemic Target Lesion Revascularization (NCT00433966)
Timeframe: 1 year
Intervention | Participants (Count of Participants) |
---|---|
Stent Arm - Paclitaxel-Eluting Stent | 98 |
Stent Arm - Bare Metal Stent | 54 |
Number of Participants With Segment Binary Angiographic Restenosis (13-month Angiographic Subset). (NCT00433966)
Timeframe: 13 months
Intervention | Participants (Count of Participants) |
---|---|
Stent Arm - Paclitaxel-Eluting Stent | 102 |
Stent Arm - Bare Metal Stent | 76 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
Intervention | Participants (Count of Participants) |
---|---|
Placebo + Ticagrelor | 141 |
Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
Intervention | Participants (Count of Participants) |
---|---|
Placebo + Ticagrelor | 135 |
Aspirin + Ticagrelor | 137 |
Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions. (NCT00552669)
Timeframe: Follow up will be conducted by the coordinating Center at 18 months of follow up
Intervention | US dollars (Mean) |
---|---|
Oral Sirolimus + Bare Metal Stent | 5483 |
Drug Eluting Stents | 7658.2 |
Efficacy end point was TVR as revasacularization of the treated vessel. (NCT00552669)
Timeframe: 18 months
Intervention | vessels (Number) |
---|---|
Oral Sirolimus + Bare Metal Stent | 14 |
Drug Eluting Stents | 15 |
Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke. (NCT00552669)
Timeframe: 18 Months
Intervention | participants (Number) | |||
---|---|---|---|---|
MACCE | Death | Acute Myocardial Infarction | Stroke | |
Drug Eluting Stents | 15 | 7 | 9 | 1 |
Oral Sirolimus + Bare Metal Stent | 9 | 3 | 6 | 0 |
Assessment of vascular healing 6 months after Resolute Integrity placement in non-diabetic patients and patients with non-insulin dependent diabetes presenting with acute coronary syndrome (ACS) using optical frequency domain imaging (OFDI). Vascular healing will be measured by percent covered stents as determined by OFDI. A higher percentage of stent coverage indicates increased endothelial regrowth, which is an essential component for the maintenance of long-term luminal patency. (NCT01794949)
Timeframe: 6 months
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
85% up to 90% stent coverage | 90% up to 95% stent coverage | 95% or greater percent stent coverage | |
NIDDM Patients Receiving the Resolute Stent | 0 | 1 | 0 |
Non-diabetic Patients Receiving the Resolute Stent | 1 | 3 | 1 |
41 reviews available for ticlopidine and Coronary Restenosis
Article | Year |
---|---|
Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; | 2017 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coro | 2014 |
The year in interventional cardiology.
Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clopidogrel; Co | 2008 |
Coronary artery stents: II. Perioperative considerations and management.
Topics: Anesthesia, Conduction; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; | 2008 |
[Drug-eluting stents: implications for modern coronary revascularization].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Bias; Clopidogrel; Comorbidity; Coronary Artery Bypass; Cor | 2009 |
Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Drug Therapy, Combination; Electr | 2009 |
Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Humans; | 2009 |
The year in interventional cardiology.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiograp | 2010 |
[Dilemma between gastroprotection and cardiovascular prevention].
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; | 2010 |
Is prasugrel more effective than clopidogrel at preventing future cardiac events?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Humans; Piperazines; Platelet Aggr | 2011 |
Personalized antiplatelet therapy: review of the latest clinical evidence.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; | 2011 |
Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment.
Topics: Blood Component Transfusion; Catheters, Indwelling; Clopidogrel; Coagulants; Coronary Artery Disease | 2011 |
Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Bioco | 2011 |
Cilostazol and primary-PCI: mirage or good alternative?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol; | 2012 |
The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Confidence Intervals; Coronary Art | 2012 |
Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Therapy, Combin | 2013 |
A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Com | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil | 2012 |
Controversies in the use & implementation of drug-eluting stent technology.
Topics: Absorbable Implants; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coated Materials, Biocompa | 2012 |
[Antiproliferative coated stents and intracoronary brachytherapy: common traits and differences].
Topics: Brachytherapy; Cell Division; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coated Materials, B | 2002 |
Combination antiplatelet therapy: implications for pharmacists.
Topics: Adult; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Eptifibatide; Female; H | 2002 |
[Endovascular brachytherapy to prevent restenosis after angioplasty].
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Brachyth | 2003 |
Sirolimus-eluting stents: a review of experimental and clinical findings.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Animals; Aspirin; Clopidogrel; Coronary Angiography | 2002 |
[Anti thrombotic therapy after coronary thrombolysis].
Topics: Anticoagulants; Aspirin; Coronary Restenosis; Drug Therapy, Combination; Fibrinolytic Agents; Hepari | 2003 |
Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Corona | 2004 |
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; | 2004 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Bl | 2004 |
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Contraindic | 2004 |
[Advances in adjunctive pharmacological therapy for percutaneous coronary interventions].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Catheterization; Clopi | 2005 |
[Triplex antithrombotic therapy after coronary-stent implantation (that is absent from recommendation)].
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; Coumarins; Drug Ther | 2005 |
[PCI: state of the art].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Humans; Japan; P | 2006 |
Aspirin and clopidogrel resistance: consideration and management.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topi | 2006 |
Understanding and minimizing late thrombosis of drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug Delivery Systems; Humans; Pla | 2007 |
[The best of interventional cardiology in 2006].
Topics: Angioplasty, Balloon, Coronary; Cardiology; Cardiovascular Diseases; Clinical Trials as Topic; Clopi | 2007 |
[Stents in interventional cardiology].
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aspirin; Clop | 2007 |
[Cardiology 2007].
Topics: Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Cholesterol; Clopidogrel; Coronary Ar | 2007 |
Clopidogrel and risk for acute coronary events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Human | 2007 |
Mortality benefit from unrestricted access to clopidogrel: too good to be true?
Topics: Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Coronary Restenosis; Drug Prescriptions; Health | 2008 |
Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature.
Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Anticoagulants; Catheterization; Clopidogrel | 2001 |
The WRIST series--what have we learnt?
Topics: Aged; Angioplasty, Balloon, Coronary; Brachytherapy; Clopidogrel; Cohort Studies; Coronary Restenosi | 2002 |
[Intracoronary radiation therapy in controlled and open clinical trials with afterloading systems and "hot" balloon catheters. Analysis of 6,692 patients].
Topics: Aged; Angioplasty, Balloon, Coronary; Beta Particles; Brachytherapy; Clinical Trials as Topic; Clopi | 2002 |
77 trials available for ticlopidine and Coronary Restenosis
Article | Year |
---|---|
Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials).
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Diabetes Compl | 2013 |
Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Restenosis; Female; Humans; Italy; Male; Mid | 2014 |
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D | 2014 |
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D | 2014 |
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D | 2014 |
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D | 2014 |
Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease.
Topics: Aged; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; D | 2014 |
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
Topics: Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin | 2014 |
A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; C | 2014 |
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Elu | 2015 |
Assessment of the efficacy and tolerability of clopidogrel napadisilate in Korean patients with coronary stenting: a multicenter, prospective, open-label, randomized trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Monitoring; Drug-Eluting Stent | 2015 |
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
Topics: Aged; Aged, 80 and over; Aspirin; Biocompatible Materials; Clopidogrel; Coronary Angiography; Corona | 2015 |
Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Co | 2015 |
Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Restenosis; Female; Follow-Up Studies; | 2015 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C | 2016 |
Prevalence and Predictors of Early Discontinuation of Dual-Antiplatelet Therapy After Drug-Eluting Stent Implantation in Korean Population.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Dose-Response Relationshi | 2016 |
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona | 2017 |
Treatment of bifurcation lesions using dedicated bifurcation stents versus classic bare-metal stents. Randomized, controlled trial with 12-month angiographic follow up.
Topics: Adult; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Re | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting | 2009 |
Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual
Topics: Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Dose-Response Relations | 2009 |
Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Coronary Angiography; Coron | 2009 |
Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
Topics: Aged; Angioplasty, Balloon, Coronary; Asia; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Mate | 2009 |
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C | 2009 |
Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidogrel; C | 2010 |
Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Diabete | 2010 |
In-hospital outcomes of contemporary percutaneous coronary intervention in patients with chronic total occlusion insights from the J-CTO Registry (Multicenter CTO Registry in Japan).
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disea | 2010 |
Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Restenosis; Dose-Respons | 2010 |
[Implantation of the paclitaxel-eluting stent Apollo in patients with stable angina pectoris: long-term angiographic and clinical results].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronar | 2010 |
Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Vessels | 2010 |
A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Sten
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Double-Blind M | 2011 |
Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combi | 2011 |
Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clopidogrel; Coronary Restenosi | 2011 |
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Di | 2011 |
Spot drug-eluting stenting for long coronary stenoses: long-term results of a randomized clinical study.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Coronary | 2011 |
Assessing the temporal course of neointimal hyperplasia formation after different generations of drug-eluting stents.
Topics: Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug-Eluting Stents; Fema | 2011 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
Topics: Aged; Clopidogrel; Coronary Restenosis; Coronary Vessels; Drug Administration Schedule; Drug Therapy | 2013 |
Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS.
Topics: Aspirin; Brachytherapy; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Female; Gamm | 2002 |
Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.
Topics: Aged; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Coronary Restenosis; Drug Therapy | 2002 |
Sustained platelet activation following intracoronary beta irradiation.
Topics: Angioplasty, Balloon, Coronary; Beta Particles; Blood Platelets; Brachytherapy; CD40 Ligand; Clopido | 2002 |
Sarpogrelate treatment reduces restenosis after coronary stenting.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cell Division; Coronary Angiography; | 2003 |
A paclitaxel-eluting stent for the prevention of coronary restenosis.
Topics: Angiogenesis Inhibitors; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; | 2003 |
A comparison of 1-month and 6-month clopidogrel therapy on clinical and angiographic outcome after stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Restenosis; Drug Admini | 2003 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Clopidogrel; Coronary Restenosis; Female; Humans; Ma | 2004 |
Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol.
Topics: Aged; Cilostazol; Coronary Restenosis; Coronary Stenosis; Equipment Design; Female; Follow-Up Studie | 2004 |
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; | 2004 |
Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary | 2004 |
Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
Topics: Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clopidogrel; Coronary Restenosis; Cost-Bene | 2004 |
The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; C | 2004 |
Direct stenting versus direct stenting followed by centered beta-radiation with intravascular ultrasound-guided dosimetry and long-term anti-platelet treatment: results of a randomized trial: Beta-Radiation Investigation with Direct Stenting and Galileo i
Topics: Aged; Aspirin; Brachytherapy; Clopidogrel; Coronary Angiography; Coronary Restenosis; Europe; Female | 2004 |
Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Cilostazol; Coronary Angiography; Coronary Artery Disease | 2004 |
Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Arter | 2004 |
Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries.
Topics: Aged; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary Angiography; Coronary Restenosis; Coronary S | 2004 |
Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiography; | 2005 |
Comparison of cilostazol and clopidogrel after successful coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Female; | 2005 |
Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biocompatibl | 2005 |
A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Coagulation; Clopidogrel; Coronary Angiography; Co | 2005 |
Impact of heparin neutralization by protamine on restenosis after coronary stent implantation.
Topics: Aged; Angina Pectoris; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Reste | 2005 |
Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary inte
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Angio | 2006 |
Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
Topics: Aged; Aspirin; Atorvastatin; Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Comb | 2007 |
Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).
Topics: Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cohort Studies; Coronary Restenosis; El | 2007 |
Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy).
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Corona | 2007 |
Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent.
Topics: Aspirin; Carbon; Cause of Death; Clopidogrel; Coated Materials, Biocompatible; Coronary Disease; Cor | 2007 |
Comparison of sarpogrelate and ticlopidine in bare metal coronary stent implantation.
Topics: Aged; Coronary Restenosis; Coronary Thrombosis; Coronary Vessels; Female; Follow-Up Studies; Humans; | 2008 |
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death, | 2007 |
Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Contraindications; Coronary Restenosis; Drug T | 2007 |
Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.
Topics: Aspirin; Biomarkers; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Coronary Resteno | 2007 |
The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I) : the one-year clinical follow-up.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Death; Drug-Eluting Stents; Female; | 2007 |
TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin | 2007 |
Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Chromium All | 2008 |
Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Clopidogr | 2008 |
Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications.
Topics: Administration, Oral; Aneurysm, False; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cere | 2001 |
Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary Restenosis; Drug Therapy, Combin | 2001 |
Late vascular response to repeat stenting for in-stent restenosis with and without radiation: an intravascular ultrasound volumetric analysis.
Topics: Blood Vessel Prosthesis Implantation; Brachytherapy; Cohort Studies; Coronary Restenosis; Disease Pr | 2002 |
155 other studies available for ticlopidine and Coronary Restenosis
Article | Year |
---|---|
Topics: Aspirin; Case-Control Studies; Clopidogrel; Coronary Restenosis; Cytochrome P-450 CYP2C19; Drug-Elut | 2021 |
Dual antiplatelet therapy after percutaneous coronary intervention: entering the final chapter?
Topics: Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Humans; Percutaneous Coronary I | 2019 |
Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model.
Topics: Adenosine; Animals; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Endothelium, Vascular; Hy | 2017 |
The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis.
Topics: Aged; Asian People; Aspirin; China; Cilostazol; Clopidogrel; Coronary Restenosis; Data Interpretatio | 2018 |
Antiplatelet Monotherapy After Percutaneous Coronary Intervention. Contemporary Long-term Outcomes and Matched Comparison With Routine Clinical Practice.
Topics: Aged; Coronary Restenosis; Female; Follow-Up Studies; Humans; Male; Percutaneous Coronary Interventi | 2018 |
Association Between Residual Platelet Reactivity on Clopidogrel Treatment and Severity of Coronary Atherosclerosis: Intrinsic Hypercoagulability as a Mediator.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans | 2019 |
Quantitative assessment of late lumen loss after biodegradable polymer and permanent polymer sirolimus-eluting stents implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Middle A | 2013 |
[Assessment of clinical and antiaggregation efficacy of generic clopidogrel 'Egithromb' in roentgenosurgical practice].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronar | 2013 |
A coronary pseudoaneurysm within a restenotic stent treated by implantation of a pericardium-covered stent and drug-eluting balloon.
Topics: Aneurysm, False; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronar | 2013 |
High on-clopidogrel treatment platelet reactivity in Thai patients with chronic stable angina scheduled for percutaneous coronary intervention.
Topics: Aged; Angina, Stable; Clopidogrel; Coronary Angiography; Coronary Restenosis; Female; Humans; Male; | 2013 |
[The CHAMPION PHOENIX study].
Topics: Adenosine Monophosphate; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; D | 2013 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected].
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hem | 2015 |
Stent selection and antiplatelet therapy duration: one size does not fit all.
Topics: Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hemorrhage; | 2015 |
A multidisciplinary approach in early stent thrombosis: Insights from optical coherence tomography and platelet reactivity testing.
Topics: Aged; Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Clopidogrel; Coronary Res | 2015 |
Effectiveness of prolonged clopidogrel-based dual antiplatelet therapy after drug-eluting stent implantation: Evidence-based meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug Combinations; Dr | 2015 |
Very late bioresorbable vascular scaffold thrombosis: a new clinical entity.
Topics: Absorbable Implants; Aged, 80 and over; Anterior Wall Myocardial Infarction; Brachytherapy; Clopidog | 2015 |
The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: A case-match study.
Topics: Angioplasty, Balloon, Coronary; Case-Control Studies; Clopidogrel; Coronary Restenosis; Cytochrome P | 2015 |
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel | 2015 |
[The ISAR-SAFE study].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug Administr | 2015 |
A case of subacute stent thrombosis after drug-coated balloon coronary angioplasty for in-stent restenosis under single anti-platelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; Coronary Vessels; D | 2017 |
Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedu | 2017 |
Etravirine as a culprit of recurrent drug-eluting in-stent restenosis in an HIV patient.
Topics: Clopidogrel; Coronary Restenosis; Drug Interactions; Drug-Eluting Stents; Female; HIV Infections; Hu | 2016 |
Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting.
Topics: Adult; Aged; Alleles; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; Body Ma | 2016 |
Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Femal | 2017 |
Chronic total occlusion--use of a 5 French guiding catheter in a 6 French guiding catheter.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Occlusion; Coronary Restenosis; Coronary | 2008 |
Percutaneous treatment of a coronary aneurysm by stent graft and drug-eluting stent implantation: a potential method to reduce stent graft restenosis.
Topics: Aged; Clopidogrel; Coronary Aneurysm; Coronary Restenosis; Drug-Eluting Stents; Humans; Male; Platel | 2008 |
Safety and efficacy of low-dose clopidogrel in Japanese patients undergoing coronary stenting: preliminary 30-day clinical outcome.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Thrombosis; Female; Huma | 2008 |
Late outcomes after drug-eluting stent implantation in "real-world" clinical practice.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coro | 2008 |
Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Case-Control Studies; Cell Adhesion | 2008 |
Clopidogrel and calcium-channel antagonists: another drug-drug interaction for the ever-wary clinician?
Topics: Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Clopidogrel; Coronary Restenosis; Coronary | 2008 |
[Perioperative discontinuation of antiplatelet therapy of patients with coronary stents. Reevaluating the risks].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Decision Tree | 2009 |
Oral triple antiplatelet therapy after percutaneous coronary intervention: subject with ongoing arguments?
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Res | 2010 |
Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-kappaB and activator protein 1 activation in pigs.
Topics: Animals; Aspirin; Clopidogrel; Coronary Restenosis; Disease Models, Animal; Drug Therapy, Combinatio | 2009 |
Treatment of multilesion coronary artery disease with simultaneous drug-eluting and bare-metal stent implantation: clinical follow up and angiographic mid-term results.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; A | 2009 |
Bridging with GP IIb/IIIa inhibitors after abdominal surgery in a patient presenting with late stent thrombosis of a drug-eluting stent and who cannot receive oral antiplatelet treatment.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elu | 2009 |
[Late thrombosis in paclitaxel-eluting stent after discontinuation of clopidogrel medication - a case report with 2-year follow-up].
Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Angiogra | 2009 |
Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosi | 2008 |
[Introduction to the topic: drug eluting stents. An underestimated problem in surgery].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Hemo | 2009 |
[Patients with coronary artery stents: when and how should operations be carried out?].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Restenosis; Dru | 2009 |
[Drug-eluting stents: implications for surgery patients].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Res | 2009 |
Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiogra | 2008 |
Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materia | 2009 |
The excel stent: a good DES, but can we really stop clopidogrel after 6 months?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Bioco | 2009 |
1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; | 2009 |
A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis.
Topics: Analysis of Variance; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting S | 2009 |
Heterogeneous arterial healing in patients following paclitaxel-eluting stent implantation: comparison with sirolimus-eluting stents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Aspirin; Coronary Angiography; Co | 2009 |
Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis | 2009 |
Regarding comparison of percutaneous coronary intervention with bare-metal and drug-eluting stents for cardiac allograft vasculopathy: problems with listing patients receiving clopidogrel for re-transplantation.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Humans; Plate | 2009 |
Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings.
Topics: Adult; Aged; Clopidogrel; Confidence Intervals; Coronary Aneurysm; Coronary Angiography; Coronary Re | 2009 |
Can we override clopidogrel resistance?
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clo | 2009 |
Drug-eluting coronary stents: many meta-analyses, little benefit.
Topics: Angina, Unstable; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Co | 2009 |
The carina angle-new geometrical parameter associated with periprocedural side branch compromise and the long-term results in coronary bifurcation lesions with main vessel stenting only.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Clopidogrel; Confidence Intervals; Co | 2009 |
Side balloon stenting of the left main bifurcation: a three-year angiographic follow-up.
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Clopidogrel; Coronary Angiography | 2009 |
Are we sure we have taken the best from clopidogrel?
Topics: Clopidogrel; Coronary Restenosis; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Ou | 2009 |
Risk and benefit of proton pump inhibitor for patients undergoing anti-platelet therapy including clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug Ther | 2009 |
High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cor | 2009 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; | 2008 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should not be continued for more than 1 year and preferably indefinitely.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Restenosis; Cor | 2008 |
Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combi | 2010 |
[Non-occlusive stent thrombosis associated to cardiocirculatory arrest].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosi | 2010 |
Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Restenosis; Coronary | 2010 |
Delays of event adjudication in the TRITON trial.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cerebral Infarction; Clopidogrel; Coronary | 2010 |
The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response.
Topics: Aged; Amlodipine; Angioplasty; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platel | 2010 |
[Balancing act in antithrombotic therapy. Between hemorrhage and embolism].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Coronar | 2010 |
Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor.
Topics: Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Confidence | 2010 |
Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary | 2010 |
[Registries of myocardial infarction in Germany. Consequences for drug therapy of patients with acute ST elevation myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Corona | 2010 |
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
Topics: Aged; Alleles; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Biotransformation; Car | 2010 |
Conflicting evidence surrounding the clopidogrel and proton pump inhibitor drug interaction.
Topics: Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial I | 2010 |
[Efficacy of stents coated with antibody against CD105 on preventing restenosis and thrombosis in minipigs].
Topics: Animals; Antibodies; Antigens, CD; Aspirin; Clopidogrel; Coronary Restenosis; Endothelial Cells; Neo | 2010 |
Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study.
Topics: Angioplasty; Aspirin; Calcinosis; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coro | 2011 |
Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Restenosis; Fem | 2011 |
Simultaneous drug-eluting and bare-metal stent implantation: long-term clinical outcome and findings of clinically indicated coronary angiography.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Confidence Intervals; Coronary Angiography; Co | 2011 |
Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Diabetes Complicati | 2011 |
Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elut | 2011 |
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorb | 2011 |
One-year outcomes with angiographic follow-up of paclitaxel-eluting balloon for the treatment of in-stent restenosis: insights from Spanish multicenter registry.
Topics: Angioplasty, Balloon; Anticoagulants; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confi | 2011 |
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistan | 2011 |
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Dru | 2012 |
[Effects of proton pump inhibitors on in-stent restenosis in patients receiving clopidogrel: a retrospective analysis].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug Antagonism; Drug Therapy, Com | 2011 |
Impact of clopidogrel on bleeding complications and survival in off-pump coronary artery bypass grafting.
Topics: Aged; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Restenosis; Dose | 2012 |
eComment. Impact of clopidogrel on bleeding complications and survival in off-pump coronary artery bypass grafting.
Topics: Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Restenosis; Female; Humans; Male; Postoperat | 2012 |
Aneurysm formation after drug-eluting balloon treatment of drug-eluting in-stent restenosis: first case report.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheters; Cardiovascular Agents; | 2012 |
Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Cilostazol; Cl | 2012 |
Double interruption of antiplatelet therapy and tirofiban "bridging" for lung cancer resection.
Topics: Acute Coronary Syndrome; Aged; Biopsy, Needle; Clopidogrel; Coronary Restenosis; Drug Administration | 2012 |
[General antithrombotic therapy practice facing fundamental change].
Topics: Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Fibrinolytic A | 2012 |
Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Coronary Restenosis; Corona | 2012 |
The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model.
Topics: Absorbable Implants; Animals; Aspirin; Cilostazol; Clopidogrel; Coated Materials, Biocompatible; Cor | 2013 |
Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Blood Platelets; | 2002 |
Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary T | 2003 |
The IST registry.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Brachytherapy; Clopidogrel; Coronary Resten | 2002 |
[Off-label use of clopidogrel after coronary stent implantation in Germany: optional or mandatory?].
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Drug Approval; Drug Costs; Drug Prescr | 2003 |
Use of restenting should be minimized with intracoronary radiation therapy for in-stent restenosis.
Topics: Brachytherapy; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Female; Humans; Male; Midd | 2003 |
Brachytherapy for in-stent restenosis: the problem is one of commitment.
Topics: Brachytherapy; Clopidogrel; Coronary Restenosis; Humans; Platelet Aggregation Inhibitors; Recurrence | 2003 |
Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Cell Adhesio | 2003 |
Intracoronary radiation to treat in-stent restenosis in six cardiac transplant patients.
Topics: Abciximab; Adult; Aged; Antibodies, Monoclonal; Arteries; Aspirin; Blood Vessel Prosthesis Implantat | 2003 |
Influence of residual stenosis after coronary stent implantation on development of restenosis and stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary Thrombo | 2003 |
Catheter based intracoronary brachytherapy leads to increased platelet activation.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Platelets; Brachythe | 2004 |
Clopidogrel induced urticarial rash in a patient with left main stem percutaneous coronary intervention: management issues.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Drug Erup | 2004 |
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona | 2004 |
[Interaction of statins with clopidogrel].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Biotransformation; Cause of Death; Clinica | 2004 |
Paclitaxel-eluting coronary stents.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Humans; Paclita | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance marks recurrent risks.
Topics: Aged; Bibliometrics; Cardiology; Clopidogrel; Cohort Studies; Coronary Restenosis; Drug Resistance; | 2004 |
Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; C-Reactive Protein; Case-Control Studies; Clopidogrel; | 2004 |
Multivessel distal sutureless off-pump coronary artery bypass grafting procedure using magnetic connectors.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Corona | 2004 |
Economics of sirolimus-eluting stents: drug-eluting stents have really arrived.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Cost-Benefit Analysis; Humans; Myo | 2004 |
[How does it work? Coronary stent implantation].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Drug T | 2004 |
Severe stenosis of anastomoses by using the symmetry aortic connector system.
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Arter | 2004 |
Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura.
Topics: Aged; Angina, Unstable; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis | 2005 |
Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Restenosis; Femal | 2005 |
Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: a rationale for the use of coagulation factor concentrates?
Topics: Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Drug Administration Schedule; Factor VIIa; | 2005 |
Very late thrombosis after implantation of sirolimus eluting stent.
Topics: Adult; Aspirin; Blood Vessel Prosthesis; Catheterization; Clopidogrel; Coronary Angiography; Coronar | 2005 |
Ischemia-driven target vessel revascularization after-primary percutaneous coronary intervention: patients at risk and their outcomes.
Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Cineangiography; Clinical Tria | 2005 |
Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting.
Topics: Abciximab; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Mono | 2005 |
Does clopidogrel improve the long-term outcome after coronary artery bypass surgery?
Topics: Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Coronary Stenosis; Humans; Platelet Aggreg | 2005 |
Letter regarding article by Valgimigli et al, "Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease".
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug Implants; H | 2005 |
[Clarification of patients at risk from the use of laminated stents].
Topics: Clopidogrel; Coronary Restenosis; Humans; Platelet Aggregation Inhibitors; Risk Factors; Stents; Tic | 2006 |
Prevention of carotid artery restenosis after sirolimus-coated stent implantation in pigs.
Topics: Alloys; Angioplasty, Balloon, Coronary; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; A | 2006 |
Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: insights from the TRUE (Taxusin Real-life Usage Evaluation) Study.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Female; Humans; Male; Middle Aged; Mult | 2006 |
[The effect of paclitaxel-eluting stents on restenosis].
Topics: Animals; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Restenosis; Coronary | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Rest | 2006 |
Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Cardiomyopathy, Dilated; Clopidogrel; Coronary Artery Bypass; Corona | 2006 |
Clopidogrel desensitization.
Topics: Aged; Angioplasty; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Desensitization, Immun | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop | 2006 |
Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study.
Topics: Aged; Aspirin; Coronary Restenosis; Coronary Thrombosis; Disease Progression; Female; Humans; Immuno | 2006 |
Long-term clinical outcome of patients treated with beta-brachytherapy in routine clinical practice.
Topics: Aspirin; Brachytherapy; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Female; Follow-Up Studi | 2007 |
End-stage renal disease and drug-eluting stents: one small step forward.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Coronary Restenosis; Humans; I | 2006 |
Clinical and angiographic outcomes of sirolimus-eluting stents implantation in Japanese patients in daily practice.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Coronary Restenosis; C | 2006 |
Premature discontinuation of antiplatelet therapy in patients with drug-eluting coronary stents.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Vessels; Delayed-Action Preparations; Humans; Pa | 2006 |
Effectiveness of a sirolimus-eluting stent (Cypher) for diffuse in-stent restenosis inside a bare metal stent.
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; Fibrinolytic Agents; Foll | 2006 |
Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery.
Topics: Aged; Clopidogrel; Coated Materials, Biocompatible; Coronary Restenosis; Drug Administration Schedul | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
[Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction].
Topics: Aged; Coronary Restenosis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggreg | 2006 |
Drug eluting stents.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug Implants; Humans; Platelet Ag | 2006 |
Stent thrombosis: consider also low response to antiplatelets.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Implants; Humans; Platelet Aggr | 2007 |
Stent thrombosis: patient card on discontinuing clopidogrel is available.
Topics: Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Implants; Humans; Medical Records; Plate | 2007 |
Severe neutropenia under clopidogrel treatment three weeks after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fem | 2007 |
Late blood clots tarnish drug-coated stents. Uncommon complication raises questions about who really needs a drug-coated stent and how long to continue drug therapy after getting one.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Drug Implants; Forecasting; Foreign Bodies; Humans; Plate | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
[Interindividual variability in the laboratory response to the aspirin-clopidogrel combination: are patients with stent occlusion "resistant" to treatment?].
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Clopidogrel; Colla | 2007 |
[Treatment of intrastent restenosis by drug eluting stents: experience from one cardiology centre].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Clopidogrel; Coronary Angiography; Coronar | 2007 |
Clopidogrel and stent thrombosis after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Thrombo | 2007 |
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angi | 2007 |
Duration of clopidogrel therapy after placement of drug-eluting intracoronary stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Delivery Systems; Hu | 2007 |
[Analysis of clinical factors that influence re-stenosis after percutaneous coronary stenting].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Restenosis; Fe | 2007 |
Angiographic and procedural correlates of stent thrombosis after intracoronary implantation of drug-eluting stents.
Topics: Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; He | 2007 |
Coronary artery stents and non-cardiac surgery.
Topics: Clopidogrel; Coronary Restenosis; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Pract | 2008 |
Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents.
Topics: Aged; Angiography; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Midd | 2008 |
Restrictive access to clopidogrel and mortality following coronary stent implantation.
Topics: Aged; Canada; Cause of Death; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Coronary | 2008 |
Very late thrombosis in a bare metal stent: an under-recognized problem.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Humans; Male; | 2008 |
Which patients receiving warfarin can be treated safely with a drug-eluting stent?
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Restenosis; Cor | 2008 |
Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Cor | 2008 |